具体实施方式
为了更好的说明本发明的技术内容,下面结合具体实例对本发明作进一步阐述,但该实施例并非用于限制本发明的保护范围。
通式I所示化合物的合成路线(A系列化合物的合成)
实施例1
(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的制备
(1)(Z)-4-氨基-N’-羟基-N-(3-溴-4-氟苯基)-1,2,5-噁二唑-3-甲咪的制备
在0℃,向化合物1(5g,34.96mmol)中依次滴入醋酸(5Ml),盐酸(4N)(5mL),NaNO2(2.42g,34.96mmol)的水(5mL)溶液,升温至室温反应18h,加入乙酸乙酯(25ml),分层,水相用乙酸乙酯(2*25ml)萃取,合并有机相,用饱和食盐水(25mL)洗,无水硫酸钠干燥,浓缩得中间体2(4.5g)。在氮气保护下,向化合物2(4.5g)和3-溴-4-氟苯胺(11.8g,62.0mmol)的甲醇(20ml)溶液中加入NaHCO3(7.8g,93.0mmol)的水(20ml)溶液,50℃反应12小时,TLC检测反应完全,浓缩,加入乙酸乙酯(20mL),分层,水相用乙酸乙酯(2*20mL)萃取,合并有机相,用饱和食盐水(20mL)洗,无水硫酸钠干燥,浓缩,柱层析得到(Z)-4-氨基-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(V-1)(7.32g,75%)。其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.45(s,1H),8.83(s,1H),8.08(dd,J=3.6,2.4Hz,1H),7.71(m,1H),7.60(t,J=8.8Hz,1H),6.59(s,2H)ppm.
(2)(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪(II-1)的制备
将化合物V-1(7g,22.2mmol)溶于四氢呋喃中,加入无水碳酸钾(9g,6.66mmol),催化量的KI,室温搅拌下将N-Boc-2-氯乙胺(4.0g,22.2mmol)的四氢呋喃溶液缓慢滴加到上述溶液中,室温下反应6h。反应结束后,过滤,滤液浓缩,柱层析得化合物中间体化合物(7.12g,70%)。将中间体化合物(7.12g,15.6mol)溶于乙酸乙酯(20ml)中,通入HCl的乙酸乙酯饱和溶液(10ml),室温下反应8h。反应结束后,乙酸乙酯萃取(30ml×3),合并有机相,饱和NaHCO3溶液洗涤(50ml),饱和食盐水洗涤(50ml),无水硫酸钠干燥,浓缩,柱层析得到化合物II-1(5.03g,90%).其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.42(s,1H),8.85(s,1H),7.18(t,J=8.8Hz,1H),7.10(dd,J=3.2,2.8Hz,1H),6.76(m,1H),6.05(s,1H),3.22(s,2H),2.76(s,2H)ppm.
(3)(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的制备
将咪唑[1,2-a]吡啶-6-羧酸(50mg,0.28mmol)溶于DCM中,依次加入II-1(100mg,0.28mmol),EDCI(91mg,0.48mmol),HOBt(47.25mg,0.35mmol),三乙胺(0.07ml,0.48mmol),室温下搅拌反应5h。反应结束后,加入水(20ml),乙酸乙酯萃取(20ml×3),合并有机相,用饱和NaHCO3溶液(10mL)洗涤,饱和氯化铵溶液(10mL)洗涤,水洗(10mL),无水硫酸钠干燥,浓缩,柱层析得目标化合物(116mg,85%)。
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.23(s,1H),9.86(s,1H),8.74(s,1H),8.34(s,1H),7.67(d,J=3.5Hz,1H),7.60(m,1H),7.44(s,2H),6.94(m,1H),6.78(m,1H),6.60(m,1H),6.05(s,1H),3.59-3.43(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.2,154.3,148.7,145.2,142.3,138.5,134.2,131.3,119.7,118.6,116.2,113.8,110.7,48.3,35.2.
其质谱为:MS(EI,m/z):503(M++1)。
实施例2
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.86(s,1H),8.83(s,1H),8.44(s,1H),7.71(d,J=3.6Hz,1H),7.65(m,1H),7.46(s,2H),6.93(m,1H),6.76(m,1H),6.64(m,1H),6.05(s,1H),3.35(m,2H),3.05(m,2H),1.93(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,1634.5,155.3,147.2,145.2,143.2,138.4,134.2,129.3,119.7,117.2,113.2,110.6,42.1,41.2,27.8.
其质谱为:MS(EI,m/z):517(M++1).
实施例3
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-4-氯丁胺,制得的(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丁基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.83(s,1H),8.79(s,1H),8.44(s,1H),7.91(d,J=3.5Hz,1H),7.71(m,1H),7.37(s,2H),6.86(m,1H),6.78(m,1H),6.56(m,1H),6.06(s,1H),3.25(m,2H),3.05(m,2H),1.50-1.48(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,163.5,155.2,153.3,148.7,147.2,145.2,143.2,134.4,133.2,129.3,119.2,118.6,117.2,116.7,114.2,110.2,42.1,39.2,27.8,26.1.
其质谱为:MS(EI,m/z):531(M++1).
实施例4
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-5-氯戊胺,制得的(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)戊基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.86(s,1H),8.89(s,1H),8.31(s,1H),7.78(d,J=3.5Hz,1H),7.61(m,1H),7.47(s,2H),6.96(m,1H),6.94(m,1H),6.82(m,1H),6.62(m,1H),6.06(s,1H),3.25-3.20(m,4H),1.60-1.57(m,4H),1.32(s,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.3,155.1,153.2,147.8,146.2,145.0,143.4,134.7,133.2,129.2,118.7,117.6,113.2,108.6,42.1,39.2,31.2,29.8,23.1.
其质谱为:MS(EI,m/z):545(M++1).
实施例5
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-6-氯己胺,制得的(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)己基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.79(s,1H),8.41(s,1H),7.81(d,J=3.5Hz,1H),7.70(m,1H),7.37(s,1H),6.96(m,1H),6.48(m,1H),6.36(m,1H),3.32-3.27(m,4H),1.60-1.57(m,4H),1.32(s,2H),1.20(s,2H)ppm.
其碳谱为:δ167.8,164.5,156.7,153.3,148.7,147.2,145.2,135.4,129.3,118.7,117.2,115.2,107.6,42.1,41.2,30.5,27.8,26.2.
其质谱为:MS(EI,m/z):585(M++1).
实施例6
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-7-氯庚胺,制得的(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)庚基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.63(s,1H),8.31(s,1H),7.79(d,J=3.7Hz,1H),7.65(m,1H),7.47(s,2H),6.94(m,1H),6.86(m,1H),6.67(m,1H),6.05(s,1H),3.38-3.23(m,4H),1.63-1.59(m,4H),1.36-1.28(m,6H)ppm.
其碳谱为:13C NMR(400MHz,DMSO):δ165.8,163.5,154.8,152.3,147.8,145.2,143.2,138.4,134.3,130.4,119.8,118.3,117.2,116.5,114.2,110.9,43.2,41.2,31.3,30.5,27.8,26.2,23.5.
其质谱为:MS(EI,m/z):573(M++1).
实施例7
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氟苯胺,制得的(Z)-N-(2-((4-(N-(4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.64(s,1H),8.34(s,1H),7.71(d,J=3.5Hz,1H),7.60(m,1H),7.48(s,2H),6.90(m,2H),6.75(m,2H),6.08(s,1H),3.56-3.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,157.3,152.9,147.3,145.2,138.5,134.8,134.0,133.3,129.6,120.2,116.8,115.2,48.3,37.2.
其质谱为:MS(EI,m/z):425(M++1).
实施例8
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氟苯胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.78(s,1H),8.43(s,1H),7.79(d,J=3.6Hz,1H),7.65(m,1H),7.45(s,2H),6.87(m,2H),6.54(m,2H),6.05(s,1H),3.54(m,2H),3,18(m,2H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,164.5,152.3,147.6,145.2,144.3,140.9,138.2,135.2,133.3,128.0,125.2,122.7,118.3,114.2,112.5,110.6,46.3,45.2,29.8.
其质谱为:MS(EI,m/z):439(M++1).
实施例9
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基-2-氟苯胺,制得的(Z)-N-(2-((4-(N-(4-甲氧基-2-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.75(s,1H),8.76(s,1H),8.67(s,1H),7.71(d,J=3.8Hz,1H),7.64(m,1H),7.32(s,2H),6.93(m,1H),6.72(m,1H),6.32(m,1H),6.05(s,1H),3.82(s,3H),3.44-3.34(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,164.5,159.3,153.6,149.2,147.9,145.1,138.2,135.2,130.3,118.0,116.2,114.9,110.7,104.3,56.3,48.6,39.8.
其质谱为:MS(EI,m/z):455(M++1).
实施例10
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基-2-氟苯胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-甲氧基-2-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.54(s,1H),9.85(s,1H),8.79(s,1H),8.63(s,1H),7.61(d,J=3.5Hz,1H),7.64(m,1H),7.41(s,2H),6.95(m,1H),6.72(m,1H),6.52(m,1H),6.07(s,1H),3.67(s,3H),3.34(m,2H),3.12(m,2H),1.75(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,159.3,153.2,149.0,147.2,145.9,138.2,136.2,130.3,118.6,114.2,105.9,55.8,41.8,39.8,28.8.
其质谱为:MS(EI,m/z):469(M++1).
实施例11
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(2-甲氧基乙氧基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.85(s,1H),8.73(s,1H),8.38(s,1H),7.89-7.84(m,3H),7.61(m,1H),7.55(s,2H),6.53(m,2H),6.05(s,1H),3.75(s,3H),4.31(m,2H),3.79(m,2H),3.50(m,2H),3.43(m,3H),3.23(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,152.3,149.3,147.6,145.2,138.2,135.2,130.3,128.0,116.3,115.2,114.7,76.3,69.8,57.5,46.7,39.2.
其质谱为:MS(EI,m/z):481(M++1).
实施例12
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(2-甲氧基乙氧基)苯胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.88(s,1H),8.68(s,1H),8.34(s,1H),7.79-7.74(m,3H),7.51(m,1H),7.45(s,2H),6.54(m,2H),6.05(s,1H),4.34(m,2H),3.85(s,3H),3.69(m,2H),3.52-3.44(m,5H),3.23(m,2H),1.83(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,152.3,149.3,147.6,145.2,138.2,135.2,130.3,128.0,116.3,115.2,114.7,79.3,69.8,59.5,41.7,39.2,27.6.
其质谱为:MS(EI,m/z):495(M++1).
实施例13
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3,5-二甲氧基苯胺,制得的(Z)-N-(2-((4-(N-(3,5-二甲氧基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.07(s,1H),9.88(s,1H),8.78(s,1H),8.63(s,1H),7.79(d,J=3.5Hz,1H),7.65(m,1H),7.48(s,2H),6.12(s,2H),6.07(s,1H),5.86(s,1H),3.84(s,6H),3.52-3.46(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,159.3,152.0,148.1,147.3,146.2,134.2,116.2,114.5,97.2,90.3,56.3,47.1,39.8.
其质谱为:MS(EI,m/z):467(M++1).
实施例14
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3,5-二甲氧基苯胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(3,5-二甲氧基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.07(s,1H),9.78(s,1H),8.76(s,1H),8.63(s,1H),7.71(d,J=3.5Hz,1H),7.67(m,1H),7.41(m,2H),6.23(s,2H),6.05(s,1H),5.75(s,1H),3.84(s,6H),3.52(m,2H),3.20(m,2H),1.86(s,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.2,162.5,160.3,153.2,148.9,147.0,146.2,136.2,117.2,113.5,98.2,92.3,46.3,39.8.
其质谱为:MS(EI,m/z):481(M++1).
实施例15
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为2-氟-4-(4-吡啶基氧基)苯胺,制得的(Z)-N-(2-((4-(N-(2-氟-4-(4-吡啶-基氧基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.57(s,1H),9.82(s,1H),8.73(s,1H),8.67(s,1H),8.38(d,J=6.5Hz,2H),7.78(d,J=3.5Hz,1H),7.60(m,1H),7.48(s,2H),7.05(m,2H),6.78(m,1H),6.61(m,1H),6.32(m,1H),6.05(s,1H),3.50-3.47(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,163.5,158.2,152.3,149.4,147.9,146.2,145.0,136.2,134.2,132.5,123.4,118.8,116.3,115.4,114.5,110.2,102.3,48.1,37.8.
其质谱为:MS(EI,m/z):518(M++1).
实施例16
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为2-氟-4-(4-吡啶基氧基)苯胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(2-氟-4-(4-吡啶-基氧基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.59(s,1H),9.88(s,1H),8.89(s,1H),8.63(s,1H),8.41(d,J=6.7Hz,2H),7.77(d,J=3.7Hz,1H),7.63(m,1H),7.45(m,2H),7.05(m,2H),6.83(m,1H),6.61(m,1H),6.34(m,1H),6.05(s,1H),3.54(m,2H),3.47(m,2H),1.78(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,159.2,152.3,148.4,147.9,147.3,137.2,134.2,132.5,124.7,117.8,115.5,111.2,103.3,42.3,27.8.
其质谱为:MS(EI,m/z):532(M++1).
实施例17
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(4-氨基-3-氟苯氧基)吡啶-2-胺,制得的(Z)-N-(2-((4-(N-(4-((2-氨基吡啶-4-基)氧基)-2-氟苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.59(s,1H),9.88(s,1H),8.79(s,1H),8.63(s,1H),7.83(m,1H),7.75(m,1H),7.65(m,2H),7.48(s,2H),6.83-6.80(m,2H),6.61(m,1H),6.32(s,1H),6.05(s,1H),5.80(s,1H),3.50-3.43(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.7,163.6,158.2,152.3,148.4,148.0,146.3,145.8,138.2,134.2,129.7,123.8,118.8,116.3,115.2,111.3,110.5,101.3,95.4,47.2,39.8.
其质谱为:MS(EI,m/z):533(M++1).
实施例18
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(4-氨基-3-氟苯氧基)吡啶-2-胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-((2-氨基吡啶-4-基)氧基)-2-氟苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.56(s,1H),9.87(s,1H),8.86(s,1H),8.63(s,1H),7.98(m,1H),7.79(m,1H),7.65(m,2H),7.45(s,2H),6.79-6.73(m,2H),6.51(m,1H),6.42(s,1H),6.05(s,1H),5.76(s,1H),3.56(m,2H),3.43(m,2H),1.67(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.3,159.2,152.3,149.7,148.1,147.3,146.8,145.2,138.6,134.8,134.0,130.7,123.8,117.9,116.8,115.2,114.3,110.3,101.3,97.4,41.2,39.8,27.7.
其质谱为:MS(EI,m/z):547(M++1).
实施例19
与实施例1的区别在于:将合成方法第(1)步中的3-溴-4-氟苯胺替换为4-(4-氨基-3-氟苯氧基)-N-甲基吡啶酰胺,制得的(Z)-N-(2-((4-(N-(2-氟-4-((2-(甲基氨基甲酰基)吡啶-4-基)氧基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.52(s,1H),9.88(s,1H),8.86(s,1H),8.63(m,1H),8.09-7.98(m,2H),7.76(d,J=3.5Hz,1H),7.63-7.60(m,2H),7.53(s,2H),6.82(m,1H),6.61(m,1H),6.32(m,1H),6.05(s,1H),3.51-3.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.7,164.6,163.1,160.2,158.2,152.4,151.5,147.3,146.8,145.1,138.2,134.2,130.7,123.7,118.8,116.3,115.7,114.3,113.2,110.3,109.4,48.2,39.8,26.3.
其质谱为:MS(EI,m/z):575(M++1).
实施例20
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(4-氨基-3-氟苯氧基)-N-甲基吡啶酰胺,第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(2-氟-4-((2-(甲基氨基甲酰基)吡啶-4-基)氧基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.53(s,1H),9.86(s,1H),8.88(s,1H),8.64(m,1H),8.09-7.98(m,2H),7.71(d,J=3.6Hz,1H),7.65-7.62(m,2H),7.53(s,1H),6.83(m,1H),6.56(m,1H),6.32(m,1H),6.05(s,1H),3.35(m,2H),3.15(m,2H),1.73(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,164.8,163.1,158.2,158.2,152.4,149.5,148.1,146.8,145.4,138.2,134.1,130.0,123.7,117.8,116.3,115.4,113.7,112.3,109.4,42.2,39.2,28.8,26.3.
其质谱为:MS(EI,m/z):589(M++1).
实施例21
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-环戊基苯胺,制得的(Z)-N-(2-((4-(N-(4-环戊基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06 5(s,1H),9.87(s,1H),8.78(s,1H),8.61(s,1H),7.79(d,J=3.5Hz,1H),7.60(m,1H),7.48(s,2H),6.95(m,2H),6.87(m,2H),6.05(s,1H),3.52-3.47(m,4H),2.75(m,1H),1.73-1.68(m,8H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,152.6,147.3,145.1,138.2,136.2,134.3,130.5,127.2,116.0,115.8,114.3,48.3,45.2,39.8,34.5,25.1.
其质谱为:MS(EI,m/z):475(M++1).
实施例22
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-环戊基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-环戊基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.89(s,1H),8.61(s,1H),7.71(d,J=3.5Hz,1H),7.53(m,1H),7.48(s,2H),6.95(m,2H),6.87(m,2H),6.05(s,1H),3.52(m,2H),3.22(m,2H),2.79(m,1H),1.93-1.68(m,10H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,152.3,147.3,138.6,137.2,134.8,134.2,129.6,127.6,116.0,115.8,113.3,46.3,42.8,39.8,34.6,28.5,25.1.
其质谱为:MS(EI,m/z):489(M++1).
实施例23
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-异丙基苯胺,制得的(Z)-N-(2-((4-(N-(4-异丙基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.87(s,1H),8.84(s,1H),8.67(s,1H),7.71(d,J=3.5Hz,1H),7.60(m,1H),7.48(s,2H),6.95(m,2H),6.67(m,2H),6.05(s,1H),3.52-3.47(m,4H),2.75(m,1H),1.23(d,J=6.5Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,152.3,147.6,145.2,138.2,134.3,132.5,130.3,129.6,126.2,116.3,116.0,114.5,48.3,39.8,33.2,23.1.
其质谱为:MS(EI,m/z):449(M++1).
实施例24
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-异丙基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-异丙基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.16(s,1H),9.88(s,1H),8.89(s,1H),8.66(s,1H),7.71(d,J=3.5Hz,1H),7.53(t,J=5.0Hz,1H),7.44(s,2H),6.98(m,2H),6.63(m,2H),6.05(s,1H),3.50(m,2H),3.25(m,2H),2.75(m,1H),1.87(m,2H),1.20(d,J=6.5Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.9,163.5,152.3,148.6,147.1,138.7,138.0,134.3,132.5,129.6,126.2,116.0,114.2,42.3,39.2,33.2,28.5,23.1.
其质谱为:MS(EI,m/z):463(M++1).
实施例25
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3,5-二甲基苯胺,制得的(Z)-N-(2-((4-(N-(2,5-二甲基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.87(s,1H),8.85(s,1H),8.53(s,1H),7.71(d,J=3.5Hz,1H),7.50(t,J=4.6Hz,1H),7.48(s,2H),6.85(t,J=5.6Hz,1H),6.57(s,2H),6.05(s,1H),3.50-3.45(m,4H),2.75(s,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.1,150.6,147.1,145.2,144.3,139.2,138.2,134.3,132.5,120.7,117.3,116.5,114.3,49.3,39.7,21.1.
其质谱为:MS(EI,m/z):435(M++1).
实施例26
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3,5-二甲基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(2,5-二甲基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.77(s,1H),8.63(s,1H),7.78(d,J=3.8Hz,1H),7.43(t,J=4.6Hz,1H),7.32(s,2H),6.88(t,J=5.8Hz,1H),6.53(m,2H),6.05(s,1H),3.45(m,2H),3.10(m,2H),2.78(s,6H),1.83(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.2,164.1,149.6,148.0,146.2,143.7,138.7,136.2,134.3,132.5,121.7,118.0,116.3,114.2,42.3,38.7,29.7,21.1.
其质谱为:MS(EI,m/z):449(M++1).
实施例27
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲基-3,5-三氟甲基苯胺,制得的(Z)-N-(2-((4-(N-(4-甲基-2,5-二三氟甲基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.83(s,1H),8.73(s,1H),8.61(s,1H),7.77(d,J=3.7Hz,1H),7.53(t,J=4.6Hz,1H),7.43(s,2H),7.03(s,2H),6.05(s,1H),3.50-3.45(m,4H),2.18(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.1,150.6,148.1,145.3,142.5,136.2,134.3,134.0,132.5,128.6,123.2,118.3,116.2,115.6,114.1,48.3,38.1,15.2.
其质谱为:MS(EI,m/z):557(M++1).
实施例28
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲基-3,5-三氟甲基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-甲基-2,5-二三氟甲基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.05(s,1H),9.78(s,1H),8.77(s,1H),8.36(s,1H),7.65(d,J=3.7Hz,1H),7.49(t,J=4.6Hz,1H),7.48(s,2H),7.03(s,2H),6.05(s,1H),3.35(m,2H),3.10(m,2H),2.13(s,3H),1.78(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.2,152.3,147.6,145.0,142.1,138.2,134.3,132.5,129.5,128.7,123.2,118.0,117.3,115.2,112.3,42.3,38.9,28.7,16.1.
其质谱为:MS(EI,m/z):571(M++1).
实施例29
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1H-吡唑-1-基)苯胺,制得的(Z)-N-(2-((4-N-(4-(1H-吡唑-1-基)苯基-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.83(s,1H),8.41(s,1H),7.98(m,1H),7.87(m,1H),7.71(d,J=3.7Hz,1H),7.53-7.46(m,5H),6.80(s,2H),6.46(t,J=3.4Hz,1H),6.05(s,1H),3.55-3.47(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.1,152.3,147.3,145.5,141.2,138.6,135.2,134.3,134.0,132.2,129.6,126.8,120.7,116.3,114.3,108.6,48.3,39.6.
其质谱为:MS(EI,m/z):473(M++1).
实施例30
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1H-吡唑-1-基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N-(4-(1H-吡唑-1-基)苯基-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.26(s,1H),9.89(s,1H),8.93(s,1H),8.52(s,1H),7.98(m,1H),7.87(m,1H),7.76(d,J=3.7Hz,1H),7.53-7.46(m,5H),6.68(s,2H),6.42(d,J=3.6Hz,1H),6.15(s,1H),3.45(m,2H),3.27(m,2H),1.89(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.8,162.1,152.6,147.5,145.3,142.5,138.2,135.3,134.5,133.2,130.7,128.6,126.7,123.2,118.3,116.6,109.0,42.9,39.8,26.1.
其质谱为:MS(EI,m/z):487(M++1).
实施例31
与实施例唯一的步骤在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-(呋喃-2-基甲基)苯胺,制得的(Z)-N-(2-((4-(N-(4-((呋喃-2-基甲基)氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.83(s,1H),8.79(s,1H),7.79(d,J=3.7Hz,1H),7.55-7.58(m,6H),6.97(m,2H),6.38-6.34(m,2H),6.05(s,1H),4.85(s,1H),3.50-3.48(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,165.3,163.1,152.6,147.3,145.2,145.1,143.5,142.1,141.0,138.6,134.8,134.0,129.6,118.6,116.3,113.2,110.5,109.3,48.3,39.6,35.4.
其质谱为:MS(EI,m/z):530(M++1).
实施例32
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-(呋喃-2-基甲基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-((呋喃-2-基甲基)氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.08(s,1H),9.76(s,1H),8.83(s,1H),8.76(s,1H),7.68(d,J=4.0Hz,1H),7.56-7.52(m,6H),6.93(m,2H),6.37-6.35(m,2H),6.08(s,1H),4.79(s,1H),3.35(m,2H),3.15(m,2H),1.75(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,165.6,163.1,153.2,147.1,145.3,143.6,142.9,141.4,138.8,134.8,131.3,118.6,116.4,114.1,112.0,110.3,42.3,39.6,34.5,25.4.
其质谱为:MS(EI,m/z):544(M++1).
实施例33
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-丁基苯甲酰胺,制得的(Z)-N-(2-((4-(N-(4-(丁基氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.08(s,1H),9.76(s,1H),8.83(s,1H),8.76(s,1H),8.69(s,1H),7.71(d,J=4.0Hz,1H),7.55-7.52(m,5H),6.97(m,2H),6.08(s,1H),3.50(m,2H),3.32-3.30(m,4H),1.57(m,2H),1.32(m,2H),1.08(m,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,165.6,163.1,152.3,147.0,145.2,142.3,138.7,133.9,132.3,129.2,126.2,119.6,115.1,114.3,48.3,38.7,32.1,20.1,15.4.
其质谱为:MS(EI,m/z):506(M++1).
实施例34
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-丁基苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-(丁基氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.86(s,1H),8.87(s,1H),8.69(s,1H),8.41(s,1H),7.78(d,J=4.0Hz,1H),7.55-7.52(m,5H),6.77(m,2H),6.05(s,1H),3.35-3.32(m,4H),3.18(m,2H),3.18(m,2H),1.85(m,2H),1.58(m,2H),1.45(m,2H),0.88(m,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,165.6,164.2,150.2,147.1,145.4,141.2,137.7,134.9,134.0,131.3,126.2,118.6,116.3,114.1,42.3,39.3,32.2,28.7,19.1,13.4.
其质谱为:MS(EI,m/z):520(M++1).
实施例35
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-乙基苯甲酰胺,制得的(Z)-N-(2-((4-(N-(4-(乙基氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.26(s,1H),9.89(s,1H),8.88(s,1H),8.78(s,1H),8.41(s,1H),7.79(d,J=3.5Hz,1H),7.55-7.52(m,5H),6.93(m,2H),6.05(s,1H),3.50(m,2H),3.32-3.29(m,4H),1.07(m,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,165.6,163.1,152.3,148.0,146.5,141.3,136.8,134.9,132.7,123.9,118.6,116.2,114.3,49.6,34.7,32.3,15.4.
其质谱为:MS(EI,m/z):478(M++1).
实施例36
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-乙基苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-(乙基氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.87(s,1H),8.83(s,1H),8.79(s,1H),8.46(s,1H),7.89(d,J=3.5Hz,1H),7.50-7.47(m,5H),6.90(m,2H),6.12(s,1H),3.35-3.28(m,4H),3.12(m,2H),1.87(m,2H),1.04(m,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,164.6,162.1,150.3,148.5,147.2,142.3,138.8,134.7,130.8,124.2,117.6,116.4,113.4,42.6,39.8,34.7,23.3,14.8.
其质谱为:MS(EI,m/z):492(M++1).
实施例37
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-2,6-二甲基-N-(2-(哌啶-1-基)苯甲酰胺,制得的(Z)-N-(2-((4-(N-(3,5-二甲基-4-((2-哌啶-1-基)乙基氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.26(s,1H),9.89(s,1H),8.88(s,1H),8.74(s,1H),8.61(s,1H),7.81(d,J=3.9Hz,1H),7.60(t,J=4.9Hz,1H),7.48(s,2H),6.93(s,2H),6.05(s,1H),3.60(m,2H),3.50(m,2H),3.32(m,2H),2.60(m,2H),2.48(s,6H),2.32(m,4H),1.47(m,4H),1.17(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,167.6,163.1,153.2,149.5,148.0,136.8,134.9,132.7,128.8,116.5,114.3,113.4,56.2,53.4,49.6,39.2,37.7,25.3,24.6,15.4.
其质谱为:MS(EI,m/z):589(M++1).
实施例38
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-2,6-二甲基-N-(2-(哌啶-1-基)苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(3,5-二甲基-4-((2-哌啶-1-基)丙基氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.19(s,1H),9.79(s,1H),8.98(s,1H),8.78(s,1H),8.67(s,1H),7.77(d,J=3.9Hz,1H),7.67(m,1H),7.26(s,2H),6.88(s,2H),6.05(s,1H),3.60(m,2H),3.36(m,2H),3.12(m,2H),2.38(s,6H),2.22-2.20(m,6H),1.85(m,2H),1.47(m,4H),1.27(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,165.6,163.1,152.3,147.5,147.0,146.5,138.8,134.9,134.0,127.2,118.6,114.3,112.9,56.9,52.0,41.6,39.7,32.3,27.5,25.9,22.4,15.4.
其质谱为:MS(EI,m/z):603(M++1).
实施例39
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-2,6-二甲基-N-(2-(吗啉-1-基)苯甲酰胺,制得的(Z)-N-(2-((4-(N-(3,5-二甲基-4-((2-吗啉乙基)氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.86(s,1H),8.88(s,1H),8.74(s,1H),8.66(s,1H),7.79(d,J=3.9Hz,1H),7.60(t,J=5.0Hz,1H),7.48(s,2H),6.93(s,2H),6.05(s,1H),3.60(m,2H),3.52-3.50(m,6H),3.42(m,2H),2.56(m,2H),2.48(s,6H),2.32(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,165.6,164.1,152.2,147.5,147.0,145.3,138.8,134.9,134.0,128.8,116.5,114.3,112.4,69.8,55.2,54.5,49.6,40.2,36.5,17.8.
其质谱为:MS(EI,m/z):591(M++1).
实施例40
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-2,6-二甲基-N-(2-(吗啉-1-基)苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(3,5-二甲基-4-((2-吗啉丙基)氨基甲酰基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.12(s,1H),9.88(s,1H),8.92(s,1H),8.84(s,1H),8.75(s,1H),7.60(d,J=4.2Hz,1H),7.67(t,J=5.0Hz,1H),7.58(s,2H),6.99(s,2H),6.15(s,1H),3.60(m,2H),3.52(m,2H),3.42(m,2H),3.19(m,2H),2.59(m,2H),2.48(s,6H),2.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.3,165.6,164.1,152.8,147.6,147.2,144.3,138.5,133.9,132.7,129.8,127.4,116.5,115.3,113.4,66.8,53.2,52.5,41.6,38.2,35.2,27.8,18.3.
其质谱为:MS(EI,m/z):605(M++1).
实施例41
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-3-(二乙基氨基)丙酰胺,制得的(Z)-N-(2-((4-(N-(4-(3-(二乙基氨基)丙酰胺基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.26(s,1H),9.89(s,1H),8.88(s,1H),8.74(s,1H),8.61(s,1H),7.81(d,J=3.9Hz,1H),7.60(t,J=4.9Hz,1H),7.48(s,2H),6.93(s,2H),6.05(s,1H),3.60(m,2H),3.50(m,2H),3.32(m,2H),2.60(m,2H),2.48(s,6H),2.32(m,4H),1.47(m,4H),1.17(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,167.6,163.1,153.2,149.5,148.0,136.8,134.9,132.7,128.8,116.5,114.3,113.4,56.2,53.4,49.6,39.2,37.7,25.3,24.6,15.4.
其质谱为:MS(EI,m/z):549(M++1).
实施例42
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-3-(二乙基氨基)丙酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-(3-(二乙基氨基)丙酰胺基)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.12(s,1H),9.88(s,1H),8.92(s,1H),8.84(s,1H),8.75(s,1H),7.60(d,J=4.2Hz,1H),7.67(t,J=5.0Hz,1H),7.58(s,2H),6.99(s,2H),6.15(s,1H),3.60(m,2H),3.52(m,2H),3.42(m,2H),3.19(m,2H),2.59(m,2H),2.48(s,6H),2.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.3,165.6,164.1,152.8,147.6,147.2,144.3,138.5,133.9,132.7,129.8,127.4,116.5,115.3,113.4,66.8,53.2,52.5,41.6,38.2,35.2,27.8,18.3.
其质谱为:MS(EI,m/z):563(M++1).
实施例43
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)丙酰胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-丙酰胺基苯基)甲咪-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.56(s,1H),10.16(s,1H),9.88(s,1H),8.78(s,1H),8.53(s,1H),7.64(d,J=3.9Hz,1H),7.50(t,J=5.0Hz,1H),7.48(s,2H),7.08(d,J=4.9Hz,2H),6.77(d,J=5.2Hz,2H),6.05(s,1H),3.52-3.50(m,4H),2.56(m,2H),2.48(s,6H),1.02(t,J=2.8Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ170.3,165.6,163.1,153.8,147.5,145.3,138.3,134.9,133.7,128.8,116.5,115.9,114.3,49.6,37.2,30.5,10.8.
其质谱为:MS(EI,m/z):478(M++1).
实施例44
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)丙酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-丙酰胺基苯基)甲咪-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.62(s,1H),10.03(s,1H),9.79(s,1H),8.92(s,1H),8.64(s,1H),7.68(d,J=4.9Hz,1H),7.57(t,J=5.3Hz,1H),7.58(s,2H),7.02(d,J=4.8Hz,2H),6.78(d,J=5.2Hz,2H),6.15(s,1H),3.60(m,2H),3.45(m,2H),3.12(m,2H),2.48(s,2H),1.67(m,2H),1.72(m,2H),1.12(t,J=2.8Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ172.3,165.6,163.1,153.2,148.2,145.3,138.5,134.9,133.7,129.8,128.4,122.4,116.5,116.3,115.3,66.8,41.6,39.2,35.2,30.6,28.8,10.3.
其质谱为:MS(EI,m/z):492(M++1).
实施例45
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-3-氯苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(3-氯苯甲酰胺基)苯基)-N’-羟基甲咪-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.56(s,1H),10.26(s,1H),9.89(s,1H),8.74(s,1H),8.63(s,1H),7.95-7.90(m,2H),7.82(d,J=3.9Hz,1H),7.79-7.70(m,3H),7.48(s,2H),7.40(d,J=2.9Hz,2H),6.72(d,J=4.9Hz,2H),6.13(s,1H),3.42-3.40(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.3,164.6,163.1,153.8,148.5,144.3,138.2,138.9,135.7,134.2,133.2,132.7,130.9,127.8,125.4,121.3,116.9,116.0,114.3,49.6,37.2.
其质谱为:MS(EI,m/z):560(M++1).
实施例46
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-3-氯苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(3-氯苯甲酰胺基)苯基)-N’-羟基甲咪-1,2,5-噁二唑-3-基)氨基丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.43(s,1H),10.35(s,1H),9.88(s,1H),8.76(s,1H),8.53(s,1H),7.95-7.90(m,2H),7.82(d,J=3.9Hz,1H),7.69-7.60(m,3H),7.48(s,2H),7.32(d,J=2.3Hz,2H),6.78(d,J=4.9Hz,2H),6.06(s,1H),3.42(m,2H),3.12(m,2H)
ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.3,165.6,162.1,152.8,147.5,145.2,137.2,138.9,135.7,134.2,133.2,131.3,129.9,127.8,124.4,122.3,116.9,116.3,114.3,49.6,41.3,27.2.
其质谱为:MS(EI,m/z):574(M++1).
实施例47
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-3-苯氨基苯甲酰胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(3-苯氨基)苯丙酰氨基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.49(s,1H),10.16(s,1H),9.88(s,1H),8.74(s,1H),8.67(s,1H),8.23(s,2H),7.98(d,J=4.9Hz,1H),7.82(d,J=3.9Hz,1H),7.69(t,J=3.9Hz,1H),7.38-7.32(m,4H),7.08-7.02(m,3H),6.77(d,J=5.9Hz,2H),6.03(s,1H),3.42-3.40(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.3,164.7,162.1,152.8,147.5,145.3,141.3,139.2,138.0,134.7,134.2,133.2,132.7,131.9,129.8,126.7,124.4,122.3,120.7,116.9,114.3,
49.6,39.2.
其质谱为:MS(EI,m/z):633(M++1).
实施例48
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-3-苯氨基苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(3-苯氨基)苯丙酰氨基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.49(s,1H),10.16(s,1H),9.88(s,1H),8.74(s,1H),8.36(s,1H),8.30(s,2H),7.98(d,J=4.9Hz,1H),7.79(d,J=3.9Hz,1H),7.65(d,J=3.9Hz,1H),7.54(t,J=3.9Hz,1H),7.48-7.42(m,7H),7.08-7.02(m,3H),6.77(d,J=5.9Hz,2H),6.12(s,1H),3.52(m,2H),3.18(m,2H),1.72(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.2,163.7,161.1,153.8,148.5,146.4,142.3,140.0,138.2,135.7,134.6,133.2,131.9,130.9,127.8,125.7,124.4,121.3,119.7,117.2,113.9,41.6,39.2,18.3.
其质谱为:MS(EI,m/z):647(M++1).
实施例49
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-2-甲氧基乙酰胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(2-甲氧基乙酰胺基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.54(s,1H),9.87(s,1H),9.65(s,1H),8.75(s,1H),8.65(s,1H),7.79(m,1H),7.60(m,1H),7.48(d,J=3.6Hz,2H),7.32(d,J=5.6Hz,2H),6.75(d,J=5.6Hz,2H),6.04(s,1H),4.20(s,2H),3.45(m,4H),3.20(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ169.2,165.3,163.5,152.2,147.9,145.9,138.4,134.9,133.9,133.2,130.6,128.7,122.7,117.3,116.2,114.2,71.4,56.3,48.9,39.9.
其质谱为:MS(EI,m/z):494(M++H).
实施例50
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-2-甲氧基乙酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(2-甲氧基乙酰胺基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.54(s,1H),9.87(s,1H),9.65(s,1H),8.67(s,1H),8.34(s,1H),7.79(m,1H),7.60(m,1H),7.48(d,J=3.6Hz,2H),7.32(d,J=5.6Hz,2H),6.79(d,J=5.6Hz,2H),6.04(s,1H),4.30(s,2H),3.40(s,3H),3.32(m,2H),3.18(m,2H),1.88(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ169.2,165.3,162.5,152.2,147.9,145.1,138.4,134.9,133.9,133.2,130.6,128.7,122.7,117.3,116.2,114.2,71.9,57.3,41.9,38.9,28.8.
其质谱为:MS(EI,m/z):508(M++H).
实施例51
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-4-甲氧基苯甲酰胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(4-甲氧基苯甲酰胺基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),10.20(s,1H),9.87(s,1H),8.74(s,1H),8.65(s,1H),7.95(d,J=6.4Hz,2H),7.79(m,1H),7.60(m,1H),7.45(m,4H),7.05(d,J=6.4Hz,2H),6.74(d,J=6.4Hz,2H),6.04(s,1H),3.80(s,3H),3.45(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,165.2,164.4,163.6,152.9,147.9,147.2,145.6,138.4,134.9,133.9,130.2,128.6,127.7,126.5,126.7,117.9,116.3,115.2,114.3,55.4,48.9,39.9.
其质谱为:MS(EI,m/z):556(M++H).
实施例52
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为N-(4-氨基苯基)-4-甲氧基苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(4-甲氧基苯甲酰胺基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),10.20(s,1H),9.87(s,1H),8.67(s,1H),8.34(s,1H),7.95(d,J=6.4Hz,2H),7.79(m,1H),7.60(m,1H),7.45(m,4H),7.05(d,J=6.4Hz,2H),6.74(d,J=6.4Hz,2H),6.04(s,1H),3.80(s,3H),3.35(m,2H),3.15(m,2H),1.83(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,165.1,164.4,163.6,153.9,148.2,147.2,145.6,138.4,134.9,133.9,130.2,128.6,127.7,126.5,126.7,117.9,116.3,115.2,114.3,55.9,41.9,39.9,28.1.
其质谱为:MS(EI,m/z):570(M++H).
实施例53
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-苯硫基苯胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(苯硫基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.75(s,1H),8.61(m,1H),7.79(m,1H),7.63(m,1H),7.45(m,7H),7.05(m,4H),6.08(s,1H),3.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.2,152.9,147.9,145.2,138.7,136.5,135.2,134.8,134.0,132.0,131.3,129.8,128.6,127.3,125.6,116.6,115.4,114.9,48.4,39.9.
其质谱为:MS(EI,m/z):515(M++H).
实施例54
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-苯硫基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N’-羟基-N-(4-(苯硫基)苯基)甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.65(s,1H),8.34(m,1H),7.79(m,1H),7.63(m,1H),7.45(m,7H),7.05(m,4H),6.08(s,1H),3.40(m,2H),3.18(m,2H),1.80(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.5,163.2,152.9,148.9,145.2,138.4,136.5,135.6,134.8,134.2,132.0,131.1,129.8,128.6,127.3,125.6,116.6,115.4,114.2,41.4,39.2,28.3.
其质谱为:MS(EI,m/z):529(M++H).
实施例55
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((4-氯苯基)硫基)苯胺,制得的(Z)-N-(2-((4-N-(4-((4-氯苯基)硫)苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.00(s,1H),9.89(s,1H),8.75(s,1H),8.65(m,1H),7.78(m,3H),7.63(m,1H),7.45(d,J=4.8Hz,2H),7.19(d,J=4.8Hz,2H),7.08(m,4H),6.08(s,1H),3.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.2,152.9,147.9,145.2,138.7,136.5,135.1,134.3,133.2,132.8,130.8,130.0,129.8,128.6,125.3,116.6,115.4,114.9,48.4,39.9.
其质谱为:MS(EI,m/z):549(M++H).
实施例56
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((4-氯苯基)硫基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N-(4-((4-氯苯基)硫)苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并
[1,2-a]吡啶-6-甲酰胺的如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.00(s,1H),9.89(s,1H),8.65(s,1H),8.35(m,1H),7.78(m,3H),7.63(m,1H),7.45(d,J=4.8Hz,2H),7.19(d,J=4.8Hz,2H),7.08(m,4H),6.08(s,1H),3.42(m,2H),3.12(m,2H),1.82(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.2,152.9,147.9,145.2,138.7,136.5,135.1,134.3,133.2,132.8,130.8,130.0,129.8,128.6,125.3,116.6,115.4,114.9,48.4,39.9.
其质谱为:MS(EI,m/z):563(M++H).
实施例57
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-二乙氨基苯胺,制得的(Z)-N-(2-((4-N-(4-二乙氨基)苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.87(s,1H),8.75(s,1H),8.61(m,1H),7.79(m,1H),7.63(m,1H),7.48(d,J=4.8Hz,2H),6.69(d,J=4.4Hz,2H),6.46(d,J=4.4Hz,2H),6.02(s,1H),3.42(m,8H),1.29(t,J=8.4Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.2,152.9,147.1,145.2,139.7,138.5,135.2,134.8,130.7,128.6,127.0,117.0,116.3,114.8,113.6,48.4,47.6,38.4,13.9.
其质谱为:MS(EI,m/z):478(M++H).
实施例58
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-二乙氨基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N-(4-二乙氨基)苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.87(s,1H),8.65(s,1H),8.31(m,1H),7.79(m,1H),7.63(m,1H),7.48(d,J=4.8Hz,2H),6.63(d,J=4.4Hz,2H),6.36(d,J=4.4Hz,2H),6.02(s,1H),3.42(m,6H),3.12(m,2H),1.82(m,6H),1.19(t,J=8.4Hz,6H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ166.5,164.2,152.1,147.1,145.2,139.4,137.5,135.2,134.8,131.7,128.6,127.0,117.0,116.3,114.8,113.6,48.4,41.6,39.4,28.9,15.9.
其质谱为:MS(EI,m/z):492(M++H).
实施例59
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-二甲氨基苯胺,制得的(Z)-N-(2-((4-N-(4-二甲基氨基)苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.89(s,1H),8.75(s,1H),8.65(m,1H),7.79(m,1H),7.60(m,1H),7.43(d,J=4.4Hz,2H),6.75(d,J=4.4Hz,2H),6.49(d,J=4.4Hz,2H),6.03(s,1H),3.42(m,4H),3.09(s,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.2,152.9,148.5,147.9,145.2,138.7,135.2,134.8,131.3,127.3,117.6,116.6,114.4,113.9,48.4,41.4,39.9.
其质谱为:MS(EI,m/z):450(M++H).
实施例60
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-二甲氨基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N-(4-二甲氨基)苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.89(s,1H),8.65(s,1H),8.35(m,1H),7.73(m,1H),7.60(m,1H),7.45(d,J=4.4Hz,2H),6.75(d,J=4.4Hz,2H),6.46(d,J=4.4Hz,2H),6.03(s,1H),3.42(m,2H),3.12(m,2H),3.03(s,6H),1.83(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.5,164.2,152.9,148.5,147.9,145.6,138.7,135.2,134.2,131.3,125.3,117.6,116.6,114.4,113.9,41.9,41.2,39.9,28.5.
其质谱为:MS(EI,m/z):464(M++H).
实施例61
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1-吗啉基)苯胺,制得的(Z)-N-(2-((4-(N-(4-吗啉基苯基)-N’-羟基甲咪基)-1,2,5-二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.54(s,1H),9.86(s,1H),8.63(s,1H),8.32(s,1H),7.72(d,J=3.6Hz,1H),7.60(m,1H),7.48(s,2H),6.70(m,2H),6.55(m,2H),6.08(s,1H),3.73(t,J=8.0Hz,4H),3.48(m,4H),3.10(t,J=8.0Hz,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.7,163.6,157.2,152.9,147.1,145.2,138.6,134.9,134.1,133.3,129.6,119.2,114.8,115.2,66.5,53.9,48.6,39.2.
其质谱为:MS(EI,m/z):492(M++H).
实施例62
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1-吗啉基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-吗啉基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.54(s,1H),9.87(s,1H),8.76(s,1H),8.42(s,1H),7.79(d,J=3.6Hz,1H),7.64(m,1H),7.48(s,2H),6.80(m,2H),6.54(m,2H),6.05(s,1H),3.75(t,J=8.0Hz,4H),3.54(m,2H),3.18(m,2H),3.04(t,J=8.0Hz,4H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.9,164.5,152.4,147.6,145.3,144.1,140.9,138.6,135.2,133.3,128.0,125.2,122.7,118.3,114.2,112.5,110.6,66.0,54.2,46.3,45.2,29.8.
其质谱为:MS(EI,m/z):506(M++H).
实施例63
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(4-甲基哌嗪基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(4-甲基哌嗪-1-基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.09(s,1H),9.86(s,1H),8.43(s,1H),8.13(s,1H),7.71(d,J=6.4Hz,1H),7.48(m,3H),7.07(m,1H),6.69(m,2H),6.50(m,3H),6.08(s,1H),3.50-3.43(m,8H),2.38(t,J=6.4Hz,4H),2.21(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.5,148.9,147.9,145.3,140.1,136.5,134.8,134.0,133.7,132.6,127.6,126.2,117.8,115.2,114.3,113.6,57.3,52.1,48.3,46.5,39.2.
其质谱为:MS(EI,m/z):505(M++H).
实施例64
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(4-甲基哌嗪基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(4-甲基哌嗪-1-基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.39(s,1H),9.88(s,1H),8.43(s,1H),8.15(s,1H),7.73(d,J=6.4Hz,1H),7.48(m,3H),7.09(m,1H),6.69(m,2H),6.53(m,3H),6.08(s,1H),3.49(m,8H),2.38(t,J=6.4Hz,4H),2.21(s,3H),1.80(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.5,148.9,147.9,145.3,140.1,136.5,134.8,134.0,133.7,132.6,127.6,126.2,117.8,115.2,114.3,113.6,57.3,52.1,48.3,46.5,39.2,28.9.
其质谱为:MS(EI,m/z):519(M++H).
实施例65
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1-哌嗪基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(哌啶-1-基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.49(s,1H),9.82(s,1H),8.42(s,1H),8.11(s,1H),7.71(d,J=6.4Hz,1H),7.46(m,3H),7.03(m,1H),6.69(m,2H),6.50(m,3H),6.08(s,1H),3.47(m,8H),1.58(m,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.4,163.1,148.9,147.4,145.3,140.0,136.5,134.5,134.3,133.7,132.2,127.1,126.1,117.6,115.2,114.1,113.6,54.2,48.3,39.2,25.6,24.3.
其质谱为:MS(EI,m/z):490(M++H).
实施例66
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1-哌嗪基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(哌啶-1-基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.39(s,1H),9.86(s,1H),8.45(s,1H),8.17(s,1H),7.73(d,J=6.4Hz,1H),7.46(m,3H),7.06-7.00(m,1H),6.66(m,2H),6.52(m,3H),6.08(s,1H),3.46(m,8H),1.75(m,8H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.6,163.5,148.7,147.4,145.3,140.5,136.1,134.8,134.0,133.3,132.6,127.3,126.2,117.8,115.6,114.3,113.3,54.3,42.5,41.5,28.8,25.5,24.2.
其质谱为:MS(EI,m/z):504(M++H).
实施例67
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3-三氟甲基-4-(1-吗啉基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉基-3-(三氟甲基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.39(s,1H),9.86(s,1H),8.40(s,1H),8.11(s,1H),7.71(d,J=6.4Hz,1H),7.45(m,3H),7.02(m,2H),6.49(m,3H),6.01(s,1H),3.70(t,J=8.0Hz,4H),3.50(m,4H),3.14(t,J=8.0Hz,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.0,148.9,147.5,145.8,136.9,134.9,134.6,134.3,133.9,133.2,132.2,126.6,125.2,120.8,115.9,115.1,114.5,113.8,113.3,66.3,53.1,48.3,39.2.
其质谱为:MS(EI,m/z):560(M++H).
实施例68
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3-三氟甲基-4-(1-吗啉基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉基-3-(三氟甲基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.43(s,1H),9.81(s,1H),8.41(s,1H),8.13(s,1H),7.72(d,J=6.4Hz,1H),7.45(m,3H),7.01(m,2H),6.48(m,3H),6.05(s,1H),3.72(t,J=8.0Hz,4H),3.35(m,2H),3.14(m,6H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.4,163.3,148.5,147.7,145.3,136.9,135.4,134.7,134.3,133.7,133.1,132.2,126.6,125.1,120.4,115.4,115.1,114.3113.8,113.0,66.0,53.4,42.9,41.3,29.2.
其质谱为:MS(EI,m/z):574(M++H).
实施例69
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3-氟-4-(N-乙基-N’-(2-羟乙基)氨基)苯胺,制得的(Z)-N-(2-((4-(乙基(羟乙基)氨基)-3-氟苯基-N’-羟基-甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.36(s,1H),9.84(s,1H),8.41(s,1H),8.12(s,1H),7.73(d,J=6.4Hz,1H),7.45(m,3H),7.05(m,2H),6.75(s,1H),6.51(m,2H),6.26(m,1H),4.85(s,1H),4.20(t,J=7.2Hz,2H),3.73(m,2H),3.45(m,6H),1.21(t,J=8.0Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.0,156.3,148.9,147.5,145.8,136.9,135.4,134.9,134.2,133.8,132.9,127.6,126.2,116.8,115.9,114.1,112.5,105.3,61.3,58.1,48.3,47.1,39.2,12.5.
其质谱为:MS(EI,m/z):512(M++H).
实施例70
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3-氟-4-(N-乙基-N’-(2-羟乙基)氨基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(乙基(羟乙基)氨基)-3-氟苯基-N’-羟基-甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.46(s,1H),9.80(s,1H),8.44(s,1H),8.16(s,1H),7.71(d,J=6.4Hz,1H),7.42(m,3H),7.05(m,2H),6.75(s,1H),6.53(m,2H),6.26(m,1H),4.82(s,1H),4.23(t,J=7.2Hz,2H),3.71(m,2H),3.38(m,4H),3.18(m,2H),1.23(t,J=8.0Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.0,163.5,156.3,148.3,147.2,145.8,136.9,135.6,134.9,134.1,133.1,132.4,127.3,126.5,116.2,115.9,114.5,112.4,105.3,61.3,58.6,48.3,47.8,39.2,28.3,12.2.
其质谱为:MS(EI,m/z):526(M++H).
实施例71
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为2-甲氧基-4-(2,6-二甲基吗啉基)苯胺,制得的(Z)-N-(2-((4-(N-(4-(2,6-二甲基吗啉基)-2-甲氧基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.59(s,1H),9.96(s,1H),8.41(s,1H),8.11(s,1H),7.71(d,J=6.4Hz,1H),7.49(m,3H),7.00(m,2H),6.46(m,1H),6.21(m,3H),6.11(m,1H),3.90(s,3H),3.55(m,6H),3.14(m,4H),1.11(d,J=6.4Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.0,148.8,148.3,147.2,145.6,140.9,136.9,135.6,134.7,133.6,132.2,126.6,122.2,118.8,115.9,114.1,104.5,98.5,73.3,68.9,55.1,48.3,39.2,19.7.
其质谱为:MS(EI,m/z):550(M++H).
实施例72
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为2-甲氧基-4-(2,6-二甲基吗啉基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-(2,6-二甲基吗啉基)-2-甲氧基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.45(s,1H),9.94(s,1H),8.42(s,1H),8.11(s,1H),7.73(d,J=6.4Hz,1H),7.39(m,3H),7.06(m,2H),6.46(m,1H),6.21(m,3H),6.11(m,1H),3.86(s,3H),3.55(m,2H),3.30(m,4H),3.14(m,4H),1.86(m,2H),1.11(d,J=6.4Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.2,163.3,148.5,148.2,147.7,145.6,140.9,136.5,135.6,134.3,133.4,132.2,126.0,122.1,118.3,115.4,114.1,104.5,98.5,73.3,68.9,55.0,42.3,41.3,28.4,19.3.
其质谱为:MS(EI,m/z):590(M++H).
实施例73
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(3-羟基吡咯-1-基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(3-羟基吡咯-1-基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.43(s,1H),9.89(s,1H),8.46(s,1H),8.18(s,1H),7.72(d,J=6.4Hz,1H),7.45(m,3H),7.01(m,2H),6.65(m,2H),6.49(m,3H),6.05(s,1H),5.39(s,1H),3.69(m,1H),3.42(m,5H),3.15(m,3H),1.75(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.4,163.3,148.5,147.3,145.6,139.9,136.4,135.4,134.2,133.3,132.7,127.6,126.1,118.4,116.4,114.6,113.3,71.8,65.0,49.4,48.1,41.3,39.2.
其质谱为:MS(EI,m/z):492(M++H).
实施例74
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(3-羟基吡咯-1-基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(3-羟基吡咯-1-基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.33(s,1H),9.99(s,1H),8.46(s,1H),8.28(s,1H),7.72(d,J=6.4Hz,1H),7.55(m,3H),7.11(m,2H),6.65(m,2H),6.54(m,3H),6.15(s,1H),5.39(s,1H),3.69(m,1H),3.39(m,3H),3.15(m,5H),1.75(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.4,163.3,148.9,147.3,145.6,138.9,136.4,135.4,134.5,133.1,130.7,127.6,125.1,116.4,115.4,113.6,111.3,71.8,65.0,49.4,43.1,41.3,38.2,28.4.
其质谱为:MS(EI,m/z):506(M++H).
实施例75
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(吗啉-1-基磺酰基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(吗啉-1-基磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.64(s,1H),8.34(s,1H),7.71(d,J=3.6Hz,1H),7.60(m,1H),7.48(s,2H),6.90(m,2H),6.75(m,2H),6.08(s,1H),3.64(t,J=7.2Hz,4H),3.48(m,4H),2.99(t,J=7.2Hz,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,148.3,147.9,146.3,141.2,136.5,134.8,134.0,133.3,132.6,131.2,129.3,126.8,115.2,114.5,112.9,65.7,48.9,47.1,39.2.
其质谱为:MS(EI,m/z):556(M++H).
实施例76
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((吗啉-1-基磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(吗啉-1-基磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.62(s,1H),8.31(s,1H),7.71(d,J=3.6Hz,1H),7.60(m,1H),7.48(s,2H),6.90(m,2H),6.75(m,2H),6.08(s,1H),3.69(t,J=7.2Hz,4H),3.33(m,4H),2.99(t,J=7.2Hz,4H),1.80(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.9,162.5,149.3,147.9,144.3,140.2,136.5,134.8,134.0,133.3,132.6,131.2,128.3,126.8,115.2,114.5,111.9,65.7,46.9,43.1,41.3,29.2.
其质谱为:MS(EI,m/z):570(M++H).
实施例77
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((4-(甲基哌嗪-1-基)磺酰基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(4-甲基哌嗪-1-基)磺酰)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.83(s,1H),8.64(s,1H),8.30(s,1H),7.71(d,J=3.6Hz,1H),7.60(m,1H),7.48(s,2H),6.90(m,2H),6.75(m,2H),6.08(s,1H),3.54(m,4H),3.08(m,4H),2.39(m,4H),2.09(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,148.3,147.9,146.3,141.2,136.5,134.8,134.0,133.3,132.6,131.2,129.3,126.8,115.2,114.5,112.9,57.7,49.9,48.8,48.1,46.7,39.2.
其质谱为:MS(EI,m/z):569(M++H).
实施例78
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((4-(甲基哌嗪-1-基)磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(4-甲基哌嗪-1-基)磺酰)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.83(s,1H),8.64(s,1H),8.30(s,1H),7.71(d,J=3.6Hz,1H),7.60(m,1H),7.48(s,2H),6.90(m,2H),6.75(m,2H),6.08(s,1H),3.34(m,2H),3.08(m,6H),2.39(m,4H),2.09(s,3H),1.88(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,148.3,147.9,146.3,141.2,136.5,134.8,134.0,133.3,132.6,131.2,129.3,126.8,115.2,114.5,112.9,56.7,48.9,46.8,43.1,42.7,29.2.
其质谱为:MS(EI,m/z):583(M++H).
实施例79
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-叔丁基氨磺酰基)苯胺,制得的(Z)-N-(2-((4-(N-叔丁基氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.10(s,1H),9.77(s,1H),8.41(s,1H),8.13(s,1H),7.71(d,J=3.6Hz,1H),7.40(m,4H),7.20(m,2H),6.97(m,1H),6.85(m,2H),6.45(m,1H),6.08(s,1H),3.44(m,4H),1.29(s,9H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,164.5,148.3,147.9,145.3,142.2,136.5,134.8,134.0,133.3,132.6,130.2,129.3,126.8,115.2,114.5,112.9,48.7,46.3,39.9,29.2.
其质谱为:MS(EI,m/z):542(M++H).
实施例80
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-叔丁基氨磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-叔丁基氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.10(s,1H),9.77(s,1H),8.44(s,1H),8.13(s,1H),7.71(d,J=3.6Hz,1H),7.40(m,4H),7.20(m,2H),7.07(m,1H),6.80(m,2H),6.45(m,1H),6.08(s,1H),3.25(m,4H),1.88(m,2H),1.29(s,9H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,164.5,148.3,147.9,145.3,142.2,136.5,134.8,134.0,133.3,132.6,130.2,129.3,126.8,115.2,114.5,112.9,47.7,42.9,41.3,29.7.
其质谱为:MS(EI,m/z):556(M++H).
实施例81
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-(2,4-二氟苯基)氨磺酰基)苯胺,制得的(Z)-N-(2-((4-(N-(4-(2,4-二氟苯基)氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.97(s,1H),9.67(s,1H),8.41(s,1H),8.13(s,1H),7.71(d,J=3.6Hz,1H),7.47(m,5H),7.08(m,1H),6.76(m,3H),6.55(m,2H),6.08(s,1H),3.54(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,160.2,154.3,148.3,147.9,145.3,141.2,136.5,135.6,134.3,133.5,132.6,131.2,130.3,129.4,126.8,119.2,115.7,114.5,112.9,111.3,105.8,48.9,39.2.
其质谱为:MS(EI,m/z):598(M++H).
实施例82
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-(2,4-二氟苯基)氨磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-(2,4-二氟苯基)氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.97(s,1H),9.63(s,1H),8.41(s,1H),8.10(s,1H),7.72(d,J=3.6Hz,1H),7.43(m,5H),7.01(m,1H),6.76(m,3H),6.45(m,2H),6.08(s,1H),3.34(m,4H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,164.5,160.2,154.3,149.3,147.9,146.3,142.2,136.5,135.6,134.3,133.5,132.6,131.2,130.3,129.4,126.8,119.2,115.7,114.5,112.9,111.3,105.8,43.9,41.4,29.2.
其质谱为:MS(EI,m/z):612(M++H).
实施例83
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-(3-甲氧基对二氮杂苯-2-基)氨磺酰基)苯胺,制得的(Z)-N-(2-((4-N’-羟基-(N-(4-(3-甲氧基对二氮杂苯-2-基)氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,2H),9.97(s,1H),8.44(s,1H),8.13(s,1H),8.03(m,1H),7.71(d,J=3.6Hz,1H),7.50(m,6H),7.08(m,1H),6.79(m,2H),6.45(m,1H),6.08(s,1H),4.04(s,3H),3.36(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,149.3,148.9,148.1,147.5,145.3,141.2,136.5,135.4,134.5,133.3,132.6,131.9,131.3,130.5,129.3,126.8,115.8,114.5,112.2,55.7,48.9,39.0.
其质谱为:MS(EI,m/z):594(M++H).
实施例84
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-(3-甲氧基对二氮杂苯-2-基)氨磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-N’-羟基-(N-(4-(3-甲氧基对二氮杂苯-2-基)氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,2H),9.97(s,1H),8.44(s,1H),8.16(s,1H),8.03(m,1H),7.71(d,J=3.6Hz,1H),7.50(m,6H),7.08(m,1H),6.79(m,2H),6.45(m,1H),6.08(s,1H),4.04(s,3H),3.36(m,2H),3.16(m,2H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,164.5,150.3,148.9,148.1,146.5,145.3,142.2,136.5,135.4,134.5,133.3,132.6,131.9,131.3,130.5,129.3,127.8,115.8,114.5,113.2,55.7,43.9,42.1,29.0.
其质谱为:MS(EI,m/z):608(M++H).
实施例85
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-(2-羟乙基)氨磺酰基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(N-(2-羟基乙基)氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.45(s,1H),8.14(s,1H),7.71(d,J=3.6Hz,1H),7.50(m,3H),7.32(m,3H),6.99(m,1H),6.85(m,2H),6.45(m,1H),6.08(s,1H),4.85(s,1H),3.48(m,8H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.5,148.3,147.9,146.1,140.2,136.5,135.4,134.7,134.1,133.3,132.6,130.2,126.9,115.2,114.5,112.9,60.7,48.9,45.1,39.2.
其质谱为:MS(EI,m/z):530(M++H).
实施例86
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-(2-羟乙基)氨磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(N-(2-羟基乙基)氨磺酰基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.97(s,1H),8.45(s,1H),8.14(s,1H),7.76(d,J=3.6Hz,1H),7.54(m,3H),7.32(m,3H),6.99(m,1H),6.85(m,2H),6.45(m,1H),6.08(s,1H),4.65(s,1H),3.40(m,6H),3.13(m,2H),1.70(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,164.5,149.3,147.9,146.1,140.2,137.5,136.4,135.4,134.1,133.3,132.6,130.2,126.9,115.2,114.5,112.9,60.1,45.9,43.1,41.8,29.2.
其质谱为:MS(EI,m/z):544(M++H).
实施例87
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-乙基-N-丙基)氨磺酰基)苯胺,制得的(Z)-N-(2-((4-(N-(4-(N-乙基-N-丙基氨磺酰基)苯基)-N’-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.87(s,1H),8.45(s,1H),8.10(s,1H),7.71(d,J=3.6Hz,1H),7.50(m,5H),6.99(m,1H),6.75(m,2H),6.45(m,1H),6.08(s,1H),3.45(m,4H),3.18(m,4H),1.58(m,4H),1.18(t,J=7.2Hz,3H),0.89(t,J=7.2Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,164.5,149.3,147.9,146.1,141.2,136.5,135.4,134.7,133.7,132.6,130.2,128.6,126.9,115.2,114.5,112.9,52.7,48.9,41.1,39.2,21.1,12.9,11.3.
其质谱为:MS(EI,m/z):556(M++H).
实施例88
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((N-乙基-N-丙基)氨磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N-(4-(N-乙基-N-丙基氨磺酰基)苯基)-N’-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.97(s,1H),8.55(s,1H),8.19(s,1H),7.77(d,J=3.6Hz,1H),7.51(m,5H),6.99(m,1H),6.75(m,2H),6.45(m,1H),6.18(s,1H),3.25(m,6H),3.08(m,2H),1.58(m,4H),1.08(t,J=7.2Hz,3H),0.83(t,J=7.2Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ168.8,165.5,149.3,147.9,146.1,142.2,136.5,135.4,134.7,133.7,132.6,130.2,128.0,126.9,115.2,114.5,110.9,52.7,43.9,41.1,39.2,28.4,21.1,13.9,12.3.
其质谱为:MS(EI,m/z):570(M++H).
实施例89
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((4-甲基磺酰基)哌嗪-1-基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(4-甲基磺酰)哌嗪-1-基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.44(s,1H),9.87(s,1H),8.67(s,1H),8.63(s,1H),7.73(d,J=3.6Hz,1H),7.60(m,1H),7.48(m,2H),6.69(m,2H),6.50(m,2H),6.08(s,1H),3.45(m,4H),3.28(m,4H),3.19(m,4H),2.87(s,3H),2.58(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,164.5,152.3,147.9,146.1,141.2,136.5,134.7,133.7,130.2,128.6,117.2,114.5,113.9,52.7,48.9,41.1,39.2
其质谱为:MS(EI,m/z):569(M++H).
实施例90
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-((4-甲基磺酰基)哌嗪-1-基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(4-甲基磺酰)哌嗪-1-基)苯基)甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-基甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.44(s,1H),9.87(s,1H),8.67(s,1H),8.63(s,1H),7.73(d,J=3.6Hz,1H),7.60(m,1H),7.48(m,2H),6.69(m,2H),6.50(m,2H),6.08(s,1H),3.35(m,2H),3.18-3.15(m,6H),2.87(s,3H),2.48(m,4H),1.78(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ165.8,163.2,152.5 147.9,145.1,139.5,138.7,134.8,133.7,130.2,127.6,118.2,114.5,113.7,52.7,47.9,41.8,37.2,28.9.
其质谱为:MS(EI,m/z):583(M++H).
实施例91
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(甲基磺酰氨基)苯胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(甲基磺酰氨基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),10.04(s,1H),9.87(s,1H),8.40(s,1H),8.11(s,1H),7.71(d,J=3.6Hz,1H),7.50(m,3H),7.05(m,1H),6.65(d,J=4.8Hz,2H),6.48(m,3H),6.08(s,1H),3.42(m,4H),3.25(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,163.2,148.9,147.4,145.3,136.4,135.2,134.4,133.5,132.0,128.8,127.3,125.1,118.8,117.5,115.6,114.3,48.3,42.6,38.9.
其质谱为:MS(EI,m/z):500(M++H).
实施例92
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(甲基磺酰氨基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(甲基磺酰氨基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.84(s,1H),10.04(s,1H),9.87(s,1H),8.40(s,1H),8.11(s,1H),7.71(d,J=3.6Hz,1H),7.52(m,3H),7.05(m,1H),6.65(d,J=4.8Hz,2H),6.54(m,3H),6.08(s,1H),3.38(m,2H),3.25(s,3H),3.13(m,1H),1.88(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.5,164.2,149.9,147.4,145.3,136.4,135.2,134.2,133.5,132.0,127.8,126.3,125.1,118.8,117.5,115.6,114.3,43.3,42.6,41.9,29.6.
其质谱为:MS(EI,m/z):514(M++H).
实施例93
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氰基-3,5-二甲基苯胺,制得的(Z)-N-(3-((4-(N-(4-(氰基-3,5-二甲基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.40(s,1H),8.11(s,1H),7.71(d,J=3.6Hz,1H),7.50(m,3H),7.04(m,1H),6.94(s,2H),6.45(d,J=4.8Hz,2H),6.08(s,1H),3.47(m,4H),2.25(s,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,164.2,148.9,148.2,147.2,145.3,142.4,136.6,135.2,134.4,133.5,132.0,126.8,117.8,115.6,114.3,113.4,107.5,48.3,39.6,21.9.
其质谱为:MS(EI,m/z):460(M++H).
实施例94
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氰基-3,5-二甲基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的(Z)-N-(3-((4-(N-(4-(氰基-3,5-二甲基苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)咪唑并[1,2-a]吡啶-6-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.40(s,1H),8.11(s,1H),7.61(d,J=3.6Hz,1H),7.40(m,3H),7.01(m,1H),6.94(s,2H),6.35(d,J=4.8Hz,2H),6.08(s,1H),3.37(m,2H),3.17(m,2H),2.35(s,6H),1.87(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.5,164.2,149.7,148.2,147.2,145.8,142.4,136.6,135.2,134.4,133.5,132.0,126.8,117.3,115.1,114.3,113.4,108.5,42.3,41.4,29.6,21.9.
其质谱为:MS(EI,m/z):474(M++H).
实施例95
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基苯乙酸酯,制得的乙基(Z)-4-(N’-羟基-4-((2-(咪唑[1,2-a]吡啶-6-甲酰胺基)乙基)氨基)-1,2,5-噁二唑-3-甲咪)苯甲酸酯的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.40(s,1H),8.15(s,1H),7.71(d,J=3.6Hz,1H),7.48(m,5H),7.03(m,1H),6.67(d,J=4.8Hz,2H),6.44(m,1H),6.08(s,1H),4.42(q,J=9.6Hz,2H),3.35(m,4H),1.32(t,J=9.6Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.5,165.4,163.2,148.9,147.4,145.4,142.3,136.4,135.2,134.5,133.4,132.5,130.0,126.8,120.5,117.3,115.1,114.8,60.6,48.3,39.6,15.9.
其质谱为:MS(EI,m/z):479(M++H).
实施例96
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基苯乙酸酯,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,制得的乙基(Z)-4-(N’-羟基-4-((2-(咪唑[1,2-a]吡啶-6-甲酰胺基)乙基)氨基)-1,2,5-噁二唑-3-甲咪)苯甲酸酯的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.43(s,1H),8.15(s,1H),7.73(d,J=3.6Hz,1H),7.48(m,5H),7.03(m,1H),6.69(d,J=4.8Hz,2H),6.54(m,1H),6.08(s,1H),4.42(q,J=9.6Hz,2H),3.35(m,2H),3.15(m,2H),1.83(m,4H),1.32(t,J=9.6Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ168.5,166.4,163.1,148.9,147.4,145.4,141.3,136.4,135.2,134.5,133.4,132.5,131.0,127.8,120.5,117.3,115.1,114.8,60.6,43.3,42.6,29.4,15.9.
其质谱为:MS(EI,m/z):493(M++H).
实施例97
与实施例1的区别在于:将合成方法步骤第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(3-溴-4-氟苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.23(s,1H),9.86(s,1H),8.84(s,1H),8.63(dd,J=3.5,2.3Hz,1H),8.21(s,1H),7.89(m,1H),7.71(d,J=3.5Hz,1H),7.35(m,1H),6.96(m,1H),6.87(m,1H),6.76(m,1H),6.46(m,1H),6.05(s,1H),3.59-3.43(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.2,154.3,148.7,147.2,146.3,141.2,135.5,133.2,131.3,29.6,126.2,123.8,118.7,117.5,114.2,108.6,48.3,35.2.
其质谱为:MS(EI,m/z):490(M++1).
实施例98
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(3-溴-4-氟苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.86(s,1H),8.83(s,1H),8.23(dd,J=3.5,2.4Hz,1H),8.11(s,1H),7.90(m,1H),7.71(d,J=3.5Hz,1H),7.25(m,1H),6.76(m,1H),6.78(m,1H),6.76(m,1H),6.34(m,1H),6.05(s,1H),3.35(m,2H),3.05(m,2H),1.93(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,164.5,153.3,148.7,147.2,145.2,143.2,133.4,131.2,129.3,128.6,124.2,121.8,116.7,115.2,113.2,107.6,42.1,41.2,27.8.
其质谱为:MS(EI,m/z):504(M++1).
实施例99
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氟苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(4-氟苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.84(s,1H),8.63(dd,J=3.5,2.3Hz,1H),8.41(s,1H),7.89(m,1H),7.71(d,J=3.5Hz,1H),7.35(m,1H),6.86(m,1H),6.87(m,1H),6.53(m,1H),6.36(m,1H),6.08(s,1H),3.56-3.42(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.5,153.3,148.9,147.3,146.2,140.9,136.5,133.2,131.3,129.6,125.2,120.8,117.6,115.2,112.5,107.6,46.3,37.2.
其质谱为:MS(EI,m/z):412(M++1).
实施例100
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氟苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(4-氟苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.78(s,1H),8.53(dd,J=3.0,2.3Hz,1H),8.41(s,1H),7.79(m,1H),7.51(d,J=3.5Hz,1H),7.25(m,1H),6.75(m,1H),6.87(m,1H),6.54(m,1H),6.37(m,1H),6.05(s,1H),3.54-3.43(m,4H),2.35(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,164.5,152.3,147.6,145.2,144.3,140.9,138.2,135.2,133.3,128.0,125.2,122.7,118.3,114.2,112.5,110.6,46.3,45.2,29.8.
其质谱为:MS(EI,m/z):426(M++1).
实施例101
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基乙氧基苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(2-氟-4-甲氧基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.65(s,1H),8.78(s,1H),8.63(dd,J=3.2,2.4Hz,1H),8.41(s,1H),7.88(m,1H),7.77(m,2H),7.61(d,J=3.5Hz,1H),7.47(t,J=3.3Hz,1H),6.45(m,2H),6.32(m,1H),6.05(s,1H),4.34(m,2H),3.72(m,2H),3.45(s,3H),3.35-3.23(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,163.5,149.3,148.1,146.2,136.6,134.8,131.3,129.6,125.7,123.9,117.3,115.2,76.3,62.1,59.8,48.6,39.2.
其质谱为:MS(EI,m/z):468(M++1).
实施例102
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基乙氧基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(2-氟-4-甲氧基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.88(s,1H),8.87(s,1H),8.63(dd,J=3.2,2.4Hz,1H),8.41(s,1H),7.98(m,1H),7.87(m,2H),7.71(d,J=3.5Hz,1H),7.43(t,J=3.4Hz,1H),6.65(m,2H),6.42(m,1H),6.05(s,1H),4.31(m,2H),3.73(m,2H),3.45(s,3H),3.35(m,2H),3.18(m,2H),1.78(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ168.8,164.5,148.2,147.8,145.3,136.6,133.8,130.3,128.6,124.7,120.9,116.3,114.8,76.3,62.1,59.8,42.6,29.2.
其质谱为:MS(EI,m/z):482(M++1).
实施例103
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-异丙基苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(4-异丙基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.87(s,1H),8.84(s,1H),8.63(dd,J=3.2,2.4Hz,1H),8.41(s,1H),7.89(m,1H),7.71(d,J=3.5Hz,1H),7.55(t,J=4.5Hz,1H),6.95(m,2H),6.67(m,2H),6.41(d,J=3.5Hz,1H),6.05(s,1H),3.52-3.47(m,4H),2.75(m,1H),1.23(d,J=6.5Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.5,149.6,148.2,146.1,136.2,134.3,132.5,129.6,126.2,123.8,116.3,48.3,39.8,33.2,23.1.
其质谱为:MS(EI,m/z):436(M++1).
实施例104
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-异丙基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为成反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(4-异丙基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.16(s,1H),9.88(s,1H),8.89(s,1H),8.66(dd,J=3.5,2.6Hz,1H),8.41(s,1H),7.89(m,1H),7.71(d,J=3.5Hz,1H),7.53(t,J=5.0Hz,1H),6.98(m,2H),6.63(m,2H),6.41(d,J=3.5Hz,1H),6.05(s,1H),3.50(m,2H),3.25(m,2H),2.75(m,1H),1.87(m,2H),1.23(d,J=6.5Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.9,163.5,149.6,148.2,147.1,136.2,134.3,132.5,129.6,126.2,123.8,116.0,42.3,33.2,28.5,23.1.
其质谱为:MS(EI,m/z):436(M++1).
实施例105
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1H-吡唑-1-基)苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(4-(1H-吡唑-1-基)苯基-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.83(s,1H),8.63(dd,J=3.6,2.5Hz,1H),8.41(s,1H),7.98(m,1H),7.87(m,1H),7.71(d,J=3.7Hz,1H),7.53-7.46(m,4H),6.80(s,2H),6.46(d,J=3.4Hz,1H),6.05(s,1H),3.55-3.47(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,163.1,149.6,148.1,147.3,141.5,136.6,134.3,132.5,129.6,126.8,123.8,120.7,116.3,108.6,48.3,39.6.
其质谱为:MS(EI,m/z):460(M++1).
实施例106
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(1H-吡唑-1-基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换成N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换成反式-3-(3-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(4-(1H-吡唑-1-基)苯基-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-3-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.26(s,1H),9.89(s,1H),8.93(s,1H),8.74(dd,J=3.7,2.8Hz,1H),8.52(s,1H),7.98(m,1H),7.87(m,1H),7.71(d,J=3.7Hz,1H),7.53-7.46(m,4H),6.68(s,2H),6.42(d,J=3.6Hz,1H),6.15(s,1H),3.45(m,2H),3.27(m,2H),1.89(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,164.1,150.6,149.5,148.3,147.0,142.5,136.2,134.3,132.5,128.6,126.7,123.2,118.3,116.6,109.0,42.9,26.1.
其质谱为:MS(EI,m/z):474(M++1).
实施例107
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-(呋喃-2-基甲基)苯甲酰胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的N-(呋喃-2-基甲基)-4-((Z)-N’-羟基-((2-((E)-3-(吡啶-3-基)丙烯酰胺基)乙基)氨基-1,2,5-噁二唑-3-甲咪)苯甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.88(s,1H),8.83(s,1H),8.79(s,1H),8.63(dd,J=3.6,2.5Hz,1H),8.41(s,1H),7.98(m,1H),7.87(m,1H),7.71(d,J=3.7Hz,1H),7.55-7.58(m,4H),6.97(m,2H),6.46(d,J=3.4Hz,1H),6.38-6.34(m,2H),6.05(s,1H),4.85(s,1H),3.50-3.48(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,166.3,163.1,149.6,148.1,147.3,145.2,143.5,142.1,141.0,136.6,134.8,132.3,129.6,126.2,122.9,118.6,116.3,110.5,48.3,39.6,35.4.
其质谱为:MS(EI,m/z):517(M++1).
实施例108
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-(呋喃-2-基甲基)苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的N-(呋喃-2-基甲基)-4-((Z)-N’-羟基-((2-((E)-3-(吡啶-3-基)丙烯酰胺基)丙基)氨基-1,2,5-噁二唑-3-甲咪)苯甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.08(s,1H),9.76(s,1H),8.83(s,1H),8.76(s,1H),8.69(dd,J=3.5,2.7Hz,1H),8.41(s,1H),7.98(m,1H),7.88(m,1H),7.71(d,J=4.0Hz,1H),7.56-7.52(m,4H),6.93(m,2H),6.41(d,J=3.5Hz,1H),6.37-6.35(m,2H),6.08(s,1H),4.79(s,1H),3.35(m,2H),3.15(m,2H),1.75(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,165.6,163.1,149.1,148.1,147.1,145.3,143.6,142.9,141.4,136.8,133.8,131.3,129.2,126.2,123.9,117.6,114.1,112.9,112.0,42.3,37.6,25.4.
其质谱为:MS(EI,m/z):531(M++1).
实施例109
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-丁基苯甲酰胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的N-丁基-4-((Z)-N’-羟基-((2-((E)-3-(吡啶-3-基)丙烯酰胺基)乙基)氨基-1,2,5-噁二唑-3-甲咪)苯甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.08(s,1H),9.76(s,1H),8.83(s,1H),8.76(s,1H),8.69(dd,J=3.5,2.7Hz,1H),8.41(s,1H),7.98(m,1H),7.71(d,J=4.0Hz,1H),7.55-7.52(m,3H),6.97(m,2H),6.46(d,J=3.5Hz,1H),6.08(s,1H),3.50-3.46(m,4H),3.32(m,2H),1.57(m,2H),1.32(m,2H),0.78(m,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.8,167.6,163.1,149.5,148.1,147.0,142.3,136.7,133.9,132.3,129.2,126.2,124.9,119.6,115.1,48.3,38.7,20.1,15.4.
其质谱为:MS(EI,m/z):493(M++1).
实施例110
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氨基-N-丁基苯甲酰胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(3-吡啶基)丙烯酸,制得的N-丁基-4-((Z)-N’-羟基-((2-((E)-3-(吡啶-3-基)丙烯酰胺基)丙基)氨基-1,2,5-噁二唑-3-甲咪)苯甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.06(s,1H),9.86(s,1H),8.87(s,1H),8.69(s,1H),8.52(dd,J=3.5,2.7Hz,1H),8.41(s,1H),7.88(m,1H),7.71(d,J=4.0Hz,1H),7.55-7.52(m,3H),6.77(m,2H),6.36(d,J=3.5Hz,1H),6.05(s,1H),3.35-3.32(m,4H),3.18(m,2H),1.85(m,2H),1.58(m,2H),1.45(m,2H),0.88(m,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.8,165.6,164.2,149.5,148.2,147.1,143.4,137.7,134.9,131.3,128.2,126.2,123.2,118.6,114.1,42.3,39.3,32.2,28.7,19.1,13.4.
其质谱为:MS(EI,m/z):507(M++1).
实施例111
与实施例1的区别在于:将合成方法步骤第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(4-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(3-溴-4-氟苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-4-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.70(d,J=3.2Hz,2H),8.41(s,1H),7.53(d,J=3.2Hz,2H),7.32(d,J=3.6Hz,1H),6.94(m,1H),6.84(s,3H),6.08(s,1H),3.47(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,164.2,155.9,149.2,147.2,144.3,142.4,141.6,134.2,126.4,123.5,119.0,118.8,117.8,110.6,48.3,39.6.
其质谱为:MS(EI,m/z):490(M++H).
实施例112
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(4-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(3-溴-4-氟苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-4-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.70(d,J=3.2Hz,2H),8.48(s,1H),7.53(d,J=3.2Hz,2H),7.32(d,J=3.6Hz,1H),6.94(m,1H),6.84(s,3H),6.08(s,1H),3.35(m,2H),3.18(m,2H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.5,164.2,156.9,149.2,147.2,144.3,142.4,141.6,134.2,126.4,123.5,119.1,118.8,117.8,110.6,42.3,41.6,29.3.
其质谱为:MS(EI,m/z):504(M++H).
实施例113
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3-三氟甲基苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(4-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(3-三氟甲基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-4-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.70(d,J=3.2Hz,2H),8.43(s,1H),7.53(d,J=3.2Hz,2H),7.32(m,3H),6.99(m,1H),6.74(m,2H),6.04(s,1H),3.47(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.5,164.2,149.2,147.4,145.2,144.3,141.4,134.6,131.2,129.4,126.5,124.0,123.8,120.8,119.6,115.8,48.8,39.6.
其质谱为:MS(EI,m/z):462(M++H).
实施例114
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为3-三氟甲基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换成反式-3-(4-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(3-三氟甲基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-4-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.70(d,J=3.2Hz,2H),8.43(s,1H),7.55(d,J=3.2Hz,2H),7.30(m,3H),6.99(m,1H),6.74(m,2H),6.04(s,1H),3.37(m,2H),3.17(m,2H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.1,164.2,149.2,147.4,145.1,144.3,141.0,134.6,131.2,129.4,127.5,124.1,123.8,120.2,119.6,115.8,42.8,40.7,29.6.
其质谱为:MS(EI,m/z):476(M++H).
实施例115
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基乙氧基苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(4-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(2-氟-4-甲氧基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-3-(吡啶-4-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.70(d,J=3.2Hz,2H),8.41(s,1H),7.81(d,J=4.8Hz,2H),7.53(d,J=3.2Hz,2H),7.32(d,J=3.6Hz,1H),6.74(d,J=3.6Hz,1H),6.54(d,J=4.8Hz,2H),6.04(s,1H),4.31(t,J=8.4Hz,2H),3.74(t,J=8.4Hz,2H),3.54(m,4H),3.36(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.9,164.1,149.9,149.2,147.2,144.3,141.4,134.6,129.2,126.4,123.5,116.0,115.8,72.8,69.6,59.6,48.3,39.6.
其质谱为:MS(EI,m/z):468(M++H).
实施例116
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基乙氧基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为反式-3-(4-吡啶基)丙烯酸,制得的(E)-N-(2-((4-((Z)-N-(2-氟-4-甲氧基苯基)-N’-羟甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-3-(吡啶-4-基)甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.70(d,J=3.2Hz,2H),8.41(s,1H),7.82(d,J=4.8Hz,2H),7.54(d,J=3.2Hz,2H),7.31(d,J=3.6Hz,1H),6.78(d,J=3.6Hz,1H),6.54(d,J=4.8Hz,2H),6.04(s,1H),4.31(t,J=8.4Hz,2H),3.74(t,J=8.4Hz,2H),3.46(s,3H),3.29(m,2H),3.13(m,2H),1.89(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ166.9,164.1,149.9,149.2,147.2,144.3,141.4,134.6,129.2,126.4,123.5,116.0,115.8,73.8,69.2,58.6,42.3,40.6,28.4.
其质谱为:MS(EI,m/z):482(M++H).
实施例117
与实施例1的区别在于:将合成方法步骤第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-N-(3-溴-4-氟苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-1H-吡咯[3,2-c]吡啶-3-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),9.49(m,2H),8.70(s,1H),8.43(m,1H),7.38(d,J=5.2Hz,1H),6.87(m,3H),6.64(m,1H),6.02(s,1H),3.48(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,163.2,155.8,148.6,147.9,147.2,142.6,134.1,129.3,125.1,122.6,119.8,118.2,117.4,114.3,110.4,108.7,48.6,39.6.
其质谱为:MS(EI,m/z):503(M++H).
实施例118
与实施例1的区别在于:将合成方法步骤第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-N-(3-溴-4-氟苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-1H-吡咯[3,2-c]吡啶-3-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),9.49(m,2H),8.34(m,2H),7.38(d,J=5.2Hz,1H),6.87(m,3H),6.64(m,1H),6.02(s,1H),3.48(m,2H),3.13(m,2H),1.79(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,163.2,155.8,148.6,147.9,147.2,142.6,134.1,129.3,125.1,122.6,119.8,118.2,117.4,114.3,110.4,108.7,41.6,39.6,28.6.
其质谱为:MS(EI,m/z):517(M++H).
实施例119
与实施例1唯一区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-异丙基苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-N-(4-异丙基苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-1H-吡咯[3,2-c]吡啶-3-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),9.49(m,2H),8.76(s,1H),8.43(d,J=5.2Hz,1H),7.38(d,J=5.2Hz,1H),6.97(d,J=5.6Hz,2H),6.84(m,1H),6.67(d,J=5.6Hz,2H),6.02(s,1H),3.45(m,4H),2.84(m,1H),1.23(d,J=9.6Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,163.2,148.6,147.9,147.2,138.6,134.9,134.1,129.3,126.1,125.6,122.8,116.2,114.4,108.7,48.6,39.6,33.2,23.6.
其质谱为:MS(EI,m/z):449(M++H).
实施例120
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-异丙基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第三步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-N-(4-异丙基苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-1H-吡咯[3,2-c]吡啶-3-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),9.49(m,2H),8.76(s,1H),8.53(d,J=5.2Hz,1H),7.34(d,J=5.2Hz,1H),6.97(d,J=5.6Hz,2H),6.84(m,1H),6.67(d,J=5.6Hz,2H),6.02(s,1H),3.35(m,2H),3.12(m,2H),2.84(m,1H),1.75(m,2H),1.23(d,J=9.6Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,163.2,148.6,147.9,147.2,138.6,134.4,133.5,129.3,126.4,125.6,122.8,116.2,114.4,108.7,41.6,39.2,33.2,28.5,23.6.
其质谱为:MS(EI,m/z):463(M++H).
实施例121
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氟苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-N-(4-氟苯基)-N’羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-1H-吡咯[3,2-c]吡啶-3-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),9.60(s,1H),9.45(s,1H),8.64(s,1H),8.43(m,1H),7.46(m,1H),6.87(m,3H),6.75(m,2H),6.08(s,1H),3.44(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,163.2,158.3,148.9,148.1,147.4,134.5,133.4,129.7,125.7,122.6,120.2,116.6,114.9,108.9,48.9,39.2.
其质谱为:MS(EI,m/z):425(M++H).
实施例122
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-氟苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-(N-(4-氟苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-1H-吡咯[3,2-c]吡啶-3-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.10(s,1H),9.87(s,1H),9.60(s,1H),9.43(s,1H),8.64(s,1H),8.42(m,1H),7.36(m,1H),6.87(m,3H),6.75(m,2H),6.12(s,1H),3.28(m,4H),188(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.9,163.2,158.9,148.9,148.3,147.4,135.2,133.4,129.7,125.7,122.4,120.2,116.6,114.2,108.9,41.9,39.5,28.2.
其质谱为:MS(EI,m/z):439(M++H).
实施例123
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基乙氧基苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1H-吡咯[3,2-c]吡啶-3-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),9.60(s,1H),9.45(s,1H),8.64(s,1H),8.43(m,1H),7.76(m,2H),7.46(m,1H),6.87(m,1H),6.65(m,2H),6.08(s,1H),4.33(t,J=6.8Hz,2H),3.73(t,J=6.8Hz,2H),3.48(m,4H),3.35(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.2,163.2,149.5,148.9,148.1,147.4,134.5,130.4,129.3,125.7,122.6,116.6,114.9,113.9,108,72.4,69.6,58.2,48.9,39.5.
其质谱为:MS(EI,m/z):481(M++H).
实施例124
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-甲氧基乙氧基苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1H-吡咯[3,2-c]吡啶-3-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),9.60(s,1H),9.45(s,1H),8.64(s,1H),8.43(m,1H),7.76(m,2H),7.46(m,1H),6.87(m,1H),6.65(m,2H),6.08(s,1H),4.33(t,J=6.8Hz,2H),3.73(t,J=6.8Hz,2H),3.39(s,3H),3.21(m,4H),1.81(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,163.2,149.5,148.4,148.1,147.4,134.0,130.2,129.3,125.7,122.6,116.6,114.9,113.9,108,72.4,69.6,58.2,41.9,39.5,28.6.
其质谱为:MS(EI,m/z):494(M++H).
实施例125
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(吗啉-1-基磺酰基)苯胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉-1-基磺酰基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1H-吡咯[3,2-c]吡啶-3-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),9.60(s,1H),9.45(s,1H),8.44(s,1H),8.35(m,1H),7.56(m,3H),6.80(m,3H),6.04(s,1H),4.63(t,J=7.2Hz,4H),3.44(m,4H),2.93(t,J=7.2Hz,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.0,163.2,148.5,147.8,147.4,140.5,134.4,130.6,129.7,129.0,125.7,122.6,114.2,112.6,108.9,65.4,48.9,47.3,39.2.
其质谱为:MS(EI,m/z):456(M++H).
实施例126
与实施例1的区别在于:将合成方法步骤第(1)步中的3-溴-4-氟苯胺替换为4-(吗啉-1-基磺酰基)苯胺,将第(2)步中的N-Boc-2-氯乙胺替换为N-Boc-3-氯丙胺,将第(3)步中的咪唑[1,2-a]吡啶-6-羧酸替换为1H-吡咯[3,2-c]吡啶-3-羧酸,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉氨磺酰基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1H-吡咯[3,2-c]吡啶-3-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.10(s,1H),9.87(s,1H),9.62(s,1H),9.41(s,1H),8.44(s,1H),8.31(m,1H),7.56(m,3H),6.80(m,3H),6.04(s,1H),4.63(t,J=7.2Hz,4H),3.24(m,4H),2.95(t,J=7.2Hz,4H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.2,163.2,148.8,147.9,147.0,140.5,134.4,130.3,129.7,129.1,125.7,122.3,114.2,112.6,108.9,65.4,47.9,41.3,39.2,27.8.
其质谱为:MS(EI,m/z):570(M++H).
通式I所示化合物的合成路线(B系列化合物的合成路线)
实施例127
(Z)-N-(3-溴-4-氟苯基)-N’-羟基-4-((2-(3-(吡啶-3-基甲基)脲)乙基)氨基)-1,2,5-噁二唑-3-甲咪制备方法如下:
三光气(148mg,0.5mmol)溶于无水甲苯中,在0℃,氮气保护下,将3-氨甲基吡啶(108mg,1mmol)的甲苯溶液滴加到上述溶液中,然后三乙胺(0.27ml,2mmol)的甲苯溶液滴加到上述溶液中;升温至室温,反应2h;然后升温到70℃反应1h,得到化合物VII-1粗产品,浓缩,直接投入下一步反应。0℃,氮气保护下,将3-(异氰酸酯甲基)-吡啶的四氢呋喃溶液(5mL)慢慢滴加到化合物II-1(315mg,1mmol)的四氢呋喃溶液(5mL)中,升温至室温反应16h,浓缩,加入水(10mL),再加入乙酸乙酯(20mL),分层,水相用乙酸乙酯(2*10mL)萃取,合并有机相,饱和食盐水(30mL)洗,无水硫酸钠干燥,浓缩,柱层析得目标物(246mg,50%)。其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.87(m,1H),7.37(m,1H),6.90(m,2H),6.74(m,1H),6.44(s,1H),6.02(s,2H),4.48(s,2H),3.43(m,4H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,155.9,149.2,148.1,147.2,143.3,136.4,135.6,134.2,123.4,119.5,118.8,117.8,110.6,48.3,45.9,41.6.其质谱为:MS(EI,m/z):493(M++H).
实施例128
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(3-溴-4-氟苯基)-N’-羟基-4-((2-(3-(吡啶-3-基甲基)脲)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.63(s,1H),8.37(m,1H),7.87(m,1H),7.37(m,1H),6.90(m,2H),6.74(m,1H),6.45(s,1H),6.02(s,2H),4.48(s,2H),3.35(m,4H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.7,155.9,149.2,148.1,146.2,143.3,136.4,135.6,134.2,123.4,119.5,118.8,117.8,110.6,50.3,45.3,41.9,28.6.
其质谱为:MS(EI,m/z):507(M++H).
实施例129
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(3,5-二甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(3,5-二甲基苯基)-N’-羟基-4-((2-(3-(吡啶-3-基甲基)脲)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.87(m,1H),7.37(m,1H),6.80(s,2H),6.54(s,1H),6.43(s,1H),6.02(s,2H),4.48(s,2H),3.40(m,4H),2.26(s,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,148.2,147.7,147.2,144.3,139.4,136.6,135.7,134.2,123.4,119.9,117.8,49.0,45.3,41.9,21.6.
其质谱为:MS(EI,m/z):425(M++H).
实施例130
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(3,5-二甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(3,5-二甲基苯基)-N’-羟基-4-((2-(3-(吡啶-3-基甲基)脲)丙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.87(m,1H),7.37(m,1H),6.80(s,2H),6.54(s,1H),6.43(s,1H),6.02(s,2H),4.48(s,2H),3.36(m,4H),2.26(s,6H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,148.2,147.7,147.2,144.3,139.4,136.6,135.7,134.2,123.4,119.9,117.8,49.9,45.3,41.2,28.6,21.6.
其质谱为:MS(EI,m/z):439(M++H).
实施例131
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-三氟甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-4-((2-(3-(吡啶-3-基甲基)脲)乙基)氨基)-N-(4-(三氟甲基)苯基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.87(m,1H),7.37(m,3H),6.60(d,J=6.4Hz,2H),6.44(s,1H),6.02(s,2H),4.48(s,2H),3.53(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,148.9,147.8,147.3,141.3,135.6,134.9,134.3,126.4,125.5,124.8,123.8,116.6,48.3,45.9,41.6.
其质谱为:MS(EI,m/z):465(M++H).
实施例132
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-三氟甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-4-((2-(3-(吡啶-3-基甲基)脲)乙基)氨基)-N-(4-(三氟甲基)苯基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.89(m,1H),7.37(m,3H),6.60(d,J=6.4Hz,2H),6.44(s,1H),6.00(s,2H),4.46(s,2H),3.38(m,4H),1.85(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,148.9,147.8,146.3,142.3,135.6,134.9,134.3,126.4,125.5,124.8,123.4,116.6,50.3,45.9,41.6,28.9.
其质谱为:MS(EI,m/z):479(M++H).
实施例133
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-(吗啉-1-基磺酰基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(吗啉-1-基磺酰基)苯基)-4-((2-(3-吡啶-3-基甲基)脲基)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.87(m,1H),7.57(d,J=5.6Hz,2H),7.30(m,1H),6.83(d,J=5.6Hz,2H),6.44(s,1H),6.02(s,2H),4.43(s,2H),3.43(m,8H),2.93(t,J=8.8Hz,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,148.7,147.4,146.9,140.3,136.4,135.6,134.2,130.4,129.5,123.8,112.8,65.6,48.3,47.9,45.3,41.6.
其质谱为:MS(EI,m/z):546(M++H).
实施例134
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-(吗啉-1-基磺酰基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(吗啉磺酰基)苯基)-4-((2-(3-吡啶-3-基甲基)脲基)丙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.37(m,1H),7.87(m,1H),7.57(d,J=5.6Hz,2H),7.30(m,1H),6.83(d,J=5.6Hz,2H),6.44(s,1H),6.02(s,2H),4.43(s,2H),3.69(t,J=8.8Hz,4H),3.33(m,4H),2.93(t,J=8.8Hz,4H),1.83(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,148.7,147.4,146.9,140.3,136.4,135.6,134.2,130.4,129.5,123.8,112.8,65.6,50.3,47.9,45.3,41.6,29.6.
其质谱为:MS(EI,m/z):560(M++H).
实施例135
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-(2-羟基乙基)磺酰氨基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(2-羟基乙基)磺酰氨基)苯基)-4-((2-(3-吡啶-3-基甲基)脲基)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.33(m,1H),7.87(m,1H),7.37(m,2H),7.17(d,J=5.6Hz,2H),6.77(d,J=5.6Hz,2H),6.44(s,1H),6.02(s,2H),4.68(s,1H),4.48(s,2H),3.43(m,8H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,149.2,148.1,147.6,140.3,136.1,135.6,134.8,134.2,130.4,123.5,112.8,61.8,48.6,45.8,45.2,41.6.
其质谱为:MS(EI,m/z):520(M++H).
实施例136
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-(2-羟基乙基)磺酰氨基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(2-羟基乙基)磺酰氨基)苯基)-4-((2-(3-吡啶-3-基甲基)脲基)丙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.59(s,1H),8.33(m,1H),7.87(m,1H),7.37(m,2H),7.17(d,J=5.6Hz,2H),6.77(d,J=5.6Hz,2H),6.44(s,1H),6.02(s,2H),4.68(s,1H),4.48(s,2H),3.40(m,8H),1.80(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.6,157.2,149.2,148.1,147.6,140.3,136.1,135.6,134.8,134.0,130.1,123.5,112.8,61.1,50.6,45.8,45.2,41.6,29.3.
其质谱为:MS(EI,m/z):534(M++H).
实施例137
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-(4-甲基哌嗪-1-基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(4-甲基哌嗪-1-基)苯基)-4-((2-(3-吡啶-3-基甲基)硫脲基)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,2H),8.59(s,1H),8.32(m,1H),7.87(m,1H),7.30(m,2H),6.64(d,J=5.6Hz,2H),6.44(d,J=5.6Hz,2H),6.04(s,2H),4.78(s,2H),3.89(m,2H),3.44(m,6H),2.34(t,J=9.6Hz,4H),2.29(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ183.5,162.2,148.9,147.2,146.5,139.6,136.2,135.3,134.4,128.6,123.2,117.4,114.5,57.8,52.8,50.6,48.3,46.9,46.3.
其质谱为:MS(EI,m/z):511(M++H).
实施例138
与实施例127的区别在于:中将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-(4-甲基哌嗪-1-基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(4-甲基哌嗪-1-基)苯基)-4-((2-(3-吡啶-3-基甲基)硫脲基)丙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,2H),8.59(s,1H),8.32(m,1H),7.87(m,1H),7.30(m,2H),6.64(d,J=5.6Hz,2H),6.44(d,J=5.6Hz,2H),6.04(s,2H),4.72(s,2H),3.69(m,2H),3.35(m,6H),2.34(t,J=9.6Hz,4H),2.21(s,3H),1.91(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ183.2,162.2,148.9,147.2,146.5,139.6,136.2,135.3,134.4,128.6,123.2,117.4,114.5,57.8,52.8,50.6,46.3,44.9,42.3,29.4.
其质谱为:MS(EI,m/z):525(M++H).
实施例139
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-甲氧基乙氧基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)-4-((2-(3-吡啶-3-基甲基)硫脲基)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.85(s,2H),8.59(s,1H),8.37(m,1H),7.82(m,3H),7.31(m,2H),6.57(d,J=5.6Hz,2H),6.04(s,1H),4.78(s,2H),4.36(t,J=9.2Hz,2H),3.78(m,4H),3.49(m,2H),3.35(s,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ183.5,163.5,149.2,148.9,147.8,146.5,136.2,135.4,134.4,129.6,123.2,116.8,115.8,72.6,68.3,59.9,50.3,48.6,46.6.
其质谱为:MS(EI,m/z):487(M++H).
实施例140
与实施例127的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-甲氧基乙氧基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)-4-((2-(3-吡啶-3-基甲基)硫脲基)乙基)氨基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.85(s,2H),8.54(s,1H),8.37(m,1H),7.82(m,3H),7.31(m,2H),6.57(d,J=5.6Hz,2H),6.04(s,1H),4.66(s,2H),4.31(t,J=9.2Hz,2H),3.65(m,4H),3.35(s,3H),3.30(m,2H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ183.5,163.5,149.2,148.9,147.8,146.5,136.2,135.4,134.4,129.6,123.2,116.8,115.8,72.4,68.1,59.4,50.3,44.6,42.6,30.3.
其质谱为:MS(EI,m/z):501(M++H).
通式I所示化合物的合成路线(C系列化合物的合成路线)
实施例141
(Z)-N-(3-溴-4-氟苯基)-4-((2-((E)-2-氰基-3-(吡啶-4-基)胍基)乙基)氨基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪的制备,其具体步骤如下:
0℃下,将钠氢(1.53g,63.83mmol)加到DMF中,将4-氨基吡啶(5g,53.2mmol)和化合物X(9.32g,63.83mmol)依次加入到上述混悬液中,转至室温反应24h。反应结束后,加入饱和氯化铵溶液淬灭,加入NaHCO3溶液调节Ph至8,CH2Cl2萃取(50×3mL),合并有机相,饱和食盐水洗涤,浓缩,柱层析分离得到化合物IX(9g,90%)。将化合物IX(100mg,0.52mmol)和化合物II-1(186mg,0.52mmol)溶于吡啶中,加入DMAP(6mg,0.052mmol),加热到50℃反应24h。反应结束后,旋干除掉溶剂,柱层析得到目标化合物(104mg,40%)。其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.89(s,1H),8.47(d,J=5.2Hz,2H),7.35(d,J=5.2Hz,2H),6.90(m,2H),6.72(m,1H),6.02(s,1H),3.78(m,2H),3.43(m,2H),2.47(s,1H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.2,155.9,154.8,149.2,147.1,142.2,134.2,119.5,118.8,117.8,116.6,110.7,109.3,48.3,35.9.其质谱为:MS(EI,m/z):503(M++H).
实施例142
与实施例141的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(3-溴-4-氟苯基)-4-((2-((E)-2-氰基-3-(吡啶-4-基)胍基)丙基)氨基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.00(s,1H),9.86(s,1H),8.82(s,1H),8.45(d,J=5.2Hz,2H),7.35(d,J=5.2Hz,2H),6.90(m,2H),6.72(m,1H),6.06(s,1H),3.58(m,2H),3.33(m,2H),2.47(s,1H),1.80(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.1,157.2,155.9,154.1,149.2,146.1,140.2,134.2,119.5,118.8,117.8,116.6,110.7,109.3,41.3,33.9,28.4.
其质谱为:MS(EI,m/z):517(M++H).
实施例143
与实施例141的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-三氟甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-4-((2-((E)-2-氰基-3-(吡啶-4-基)胍基)乙基)氨基)-N’-羟基-N-(4-(三氟甲基)苯基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.79(s,1H),8.47(m,1H),7.37(m,4H),6.60(d,J=5.2Hz,2H),6.04(s,1H),3.78(s,2H),3.43(m,2H),2.48(s,1H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.5,155.2,150.8,147.2,141.3,134.4,126.6,125.2,124.4,117.5,116.8,110.6,48.3,35.9.
其质谱为:MS(EI,m/z):475(M++H).
实施例144
与实施例141的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-三氟甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-4-((2-((E)-2-氰基-3-(吡啶-4-基)胍基)丙基)氨基)-N’-羟基-N-(4-(三氟甲基)苯基)-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.79(s,1H),8.45(m,1H),7.37(m,4H),6.62(d,J=5.2Hz,2H),6.04(s,1H),3.58(s,2H),3.23(m,2H),2.48(s,1H),1.83(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.4,157.5,154.2,150.8,147.2,142.3,134.4,126.6,125.2,124.4,117.5,116.8,110.6,41.3,34.9,30.3.
其质谱为:MS(EI,m/z):489(M++H).
实施例145
与实施例141的区别在于:将4-氨基吡啶替换为3-氨基吡啶,制得的(Z)-N-(3-溴-4-氟苯基)-4-((2-((E)-2-氰基-3-(吡啶-3-基)胍基)乙基)氨基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.79(s,1H),8.53(m,1H),8.13(m,1H),7.43(m,1H),7.17(m,1H),6.87(m,2H),6.64(m,1H),6.02(s,1H),3.82(m,2H),3.48(m,2H),2.49(s,1H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.2,155.8,148.2,146.9,142.1,137.6,135.6,134.3,132.1,127.6,119.8,118.2,117.4,116.5,110.8,48.6,37.6.
其质谱为:MS(EI,m/z):503(M++H).
实施例146
与实施例141的区别在于:将4-氨基吡啶替换为3-氨基吡啶,将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(3-溴-4-氟苯基)-4-((2-((E)-2-氰基-3-(吡啶-3-基)胍基)乙基)氨基)-N’-羟基-1,2,5-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.79(s,1H),8.53(m,1H),8.13(m,1H),7.42(m,1H),7.15(m,1H),6.87(m,2H),6.64(m,1H),6.02(s,1H),3.52(m,2H),3.28(m,2H),2.49(s,1H),1.82(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ164.5,158.2,155.2,148.1,146.3,142.7,137.2,135.6,134.3,132.1,127.6,119.8,118.2,117.4,116.5,110.8,41.6,34.6,30.4.
其质谱为:MS(EI,m/z):517(M++H).
实施例147
与实施例141的区别在于:将4-氨基吡啶替换为3-氨基吡啶,将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-4-((2-((E)-2-氰基-3-(吡啶-3-基)胍基)乙基)氨基)-N-(4-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.79(s,1H),8.50(m,1H),8.13(m,1H),7.33(m,1H),7.17(m,1H),6.97(d,J=5.2Hz,2H),6.74(d,J=5.2Hz,2H),6.02(s,1H),3.82(m,2H),3.48(m,2H),2.49(s,1H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.2,157.8,148.2,146.9,138.6,135.6,134.1,133.3,132.1,127.6,119.8,117.2,116.4,48.6,37.6.
其质谱为:MS(EI,m/z):425(M++H).
实施例148
与实施例141的区别在于:将4-氨基吡啶替换为3-氨基吡啶,将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-4-((2-((E)-2-氰基-3-(吡啶-3-基)胍基)丙基)氨基)-N-(4-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.02(s,1H),9.84(s,1H),8.79(s,1H),8.52(m,1H),8.13(m,1H),7.33(m,1H),7.17(m,1H),6.97(d,J=5.2Hz,2H),6.74(d,J=5.2Hz,2H),6.02(s,1H),3.56(m,2H),3.38(m,2H),2.49(s,1H),1.88(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.2,157.8,148.2,146.9,138.6,135.6,134.5,133.3,132.1,127.6,119.8,117.2,116.4,41.6,34.6,29.4.
其质谱为:MS(EI,m/z):439(M++H).
通式I所示化合物的合成路线(D系列化合物的合成方法)
实施例149
(Z)-N-(2-((4-(3-溴-4-氟苯基)-N’-羟基甲咪)-1,2,5-1,2,5-噁二唑-3-基)氨基)乙基)-2-(吡啶-3-基)环丙烷-1-甲酰胺的制备,具体步骤如下:
氮气保护下,3-溴吡啶(157g,0.994mol),丙烯酸正丁酯(192g,1.50mmol),Pd(OAc)2(2.3g,10.2mmol,)、PPh3(5.2g,19.8mmol)、K2CO3(276g,2.00mol)加入到DMF(200ml)中,加热至130℃反应20h。冷却至室温,过滤,滤液浓缩,加入水,乙酸乙酯萃取(500ml×3),饱和食盐水洗涤,无水硫酸钠干燥,浓缩,柱层析得到化合物8(160g)。将化合物8(70g,0.34mol)溶于乙醇(150ml)中,将氢氧化钾(40g,0.71mol)溶于水(150ml)中,加入到上述溶液中,加热回流3h。反应结束后,用12M HCl调节Ph至6.0,沉淀析出,过滤,收集滤饼,得到化合物9(50g,98%)。将化合物9(50g,0.34mol)和N,O-二甲基羟胺盐酸盐(65g,0.67mol)溶于二氯甲烷(1L)中,然后依次加入EDCI(127g,0.66mol)和DMAP(80g,0.65mol),室温下搅拌反应2h。反应结束后,加入水200ml,二氯甲烷萃取(1L×2)萃取,合并有机相,有机相用饱和食盐水洗涤(500ml×3),无水硫酸钠干燥,浓缩,得到化合物10粗品70g。三甲基硫氧碘(145g,0.67mol)溶于DMSO(500ml)中,0℃下,将钠氢(26g,1.1mol)加入到上述溶液中。转至室温,搅拌1h,然后将化合物10(66g,0.34mol)加入到前面所述的溶液中,室温下继续反应1h。反应结束后,加入饱和氯化铵溶液(400mL)淬灭,乙酸乙酯萃取(3×1L),合并有机相,水洗(3×500mL),无水硫酸钠干燥,浓缩,柱层析得到黄色油状化合物11(56g,80%)。将化合物11(50g,0.24mol)溶于乙醇中,将氢氧化钾(40g,0.71mol)溶于水(100mL)中,加入到上述溶液中,加热回流3h,反应结束后,加入水(300mL),二氯甲烷(3×100mL)萃取,水相用12M HCl调节Ph至6.0,然后将水相浓缩得到固体,向固体中加入甲醇,过滤出去不溶物,滤液浓缩,得到34g淡黄色粗品化合物12。将化合物12(1.0g,6.13mmol)溶于无水二氯甲烷(5mL)中,加入氯化亚砜(10mL,138mmol),1滴DMF,加热至40℃,反应5h。冷却至室温,浓缩得到粗品化合物13(1.34g)。化合物II-1溶于无水DMF中,加入三乙胺(1.0g,10mmol),将制备的酰氯化合物13(0.18g,0.99mmol)溶于无水DMF中,滴加到II-1(461.82mg,1.29mmol),室温下反应4h。反应液浓缩,柱层析得到目标化合物(149mg,30%)。
合成方法如实施例1。其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.37(m,2H),8.01(s,1H),7.58(m,1H),7.12(m,1H),6.74(m,3H),6.08(s,1H),3.47(m,4H),3.17(m,1H),2.83(m,1H),1.83(m,2H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ174.5,163.2,155.9,151.2,148.2,147.3,143.4,142.6,135.2,134.5,123.4,119.0,118.8,117.8,110.6,48.3,39.6,27.8,25.2,16.4.其质谱为:MS(EI,m/z):504(M++H).
实施例150
与实施例149的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(3-溴-4-氟苯基)-N’-羟基甲咪)-1,2,5-1,2,5-噁二唑-3-基)氨基)丙基)-2-(吡啶-3-基)环丙烷-1-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.37(m,2H),8.01(s,1H),7.52(m,1H),7.11(m,1H),6.75(m,3H),6.04(s,1H),3.37(m,2H),3.17(m,3H),2.83(m,1H),1.83(m,4Hppm.
其碳谱为:13C NMR(125MHz,DMSO):δ174.5,163.2,155.9,151.2,148.2,147.3,143.4,142.6,135.2,134.5,123.4,119.0,118.8,117.8,110.6,41.3,38.6,29.4,27.8,25.2,17.4.
其质谱为:MS(EI,m/z):518(M++H).
实施例151
与实施例149的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-甲氧基乙氧基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-,2,5-噁二唑-3-基)氨基)乙基)-2-(吡啶-3-基)环丙烷-1-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.38(m,2H),8.08(s,1H),7.73(m,3H),7.22(m,1H),6.54(d,J=4.8Hz,1H),6.08(s,1H),4.32(t,J=8.4Hz,2H),3.74(t,J=8.4Hz,2H),3.54(m,4H),3.36(s,3H),3.13(m,1H),2.86(m,1H),1.89(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ174.5,164.1,150.9,149.7,149.2,148.5,147.2,143.3,135.4,134.6,129.2,123.4,116.8,114.8,72.6,69.3,58.5,48.3,39.6,26.7,24.5,17.8.
其质谱为:MS(EI,m/z):482(M++H).
实施例152
与实施例149的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-甲氧基乙氧基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-2-(吡啶-3-基)环丙烷-1-甲酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.87(s,1H),8.38(m,2H),8.08(s,1H),7.70(m,3H),7.22(m,1H),6.54(d,J=4.8Hz,1H),6.08(s,1H),4.30(t,J=8.4Hz,2H),3.72(t,J=8.4Hz,2H),3.42(s,3H),3.34(m,2H),3.18(m,3H),2.79(m,1H),1.84(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ174.5,164.1,150.9,149.7,149.2,148.5,147.2,143.3,135.4,134.6,129.2,123.4,116.8,114.8,72.6,69.3,58.5,48.3,39.6,26.7,24.5,17.8.
其质谱为:MS(EI,m/z):496(M++H).
通式I所示化合物的合成路线(E系列化合物的合成方法)
实施例153
(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的制备,具体步骤如下:
化合物II-1(1g,2.79mmol)溶于无水甲苯中,将化合物14(1.1g,5.58mmol)加入到上述溶液中,氮气保护下,升温至120℃,反应30min。冷却至室温,过滤,滤饼用甲苯洗涤,得到化合物VIII-1(1.3g,90%)。将化合物15(114mg,0.96mmol)和化合物VIII-1(500mg,0.96mmol)溶于乙醇中,升温至90℃,反应2h后,停止反应。冷却至室温,浓缩,柱层析得到目标化合物(193mg,40%)。其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.87(m,2H),6.65(m,1H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.36(m,4H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.2,155.3,150.9,148.1,147.4,146.6,142.5,134.5,133.4,124.7,119.7,118.6,117.2,110.6,58.4,57.3,48.9,41.2.其质谱为:MS(EI,m/z):505(M++H).
实施例154
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(3-溴-4-氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.89(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.87(m,2H),6.65(m,1H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.34(m,4H),1.84(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.2,158.2,154.3,150.9,148.1,147.2,146.6,142.5,134.2,133.4,124.7,119.7,118.6,117.2,110.6,58.9,57.3,49.9,41.0,28.4.
其质谱为:MS(EI,m/z):519(M++H).
实施例155
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-甲氧基乙氧基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.89(s,1H),8.60(s,1H),8.11(m,1H),7.79(m,2H),7.19(m,1H),6.57(m,2H),6.05(s,2H),5.20(s,2H),4.45(s,2H),4.33(t,J=6.8Hz,2H),3.73(t,J=6.8Hz,2H),3.48(m,4H),3.35(s,3H)ppm
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,150.9,149.7,148.1,147.4,146.7,134.5,133.4,129.7,124.7,116.6,115.2,72.4,69.5,59.4,58.1,57.3,48.7,41.2
其质谱为:MS(EI,m/z):482(M++H).
实施例156
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-甲氧基乙氧基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-(2-甲氧基乙氧基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.89(s,1H),8.60(s,1H),8.11(m,1H),7.79(m,2H),7.19(m,1H),6.57(m,2H),6.05(s,2H),5.20(s,2H),4.45(s,2H),4.33(t,J=6.8Hz,2H),3.73(t,J=6.8Hz,2H),3.42(s,3H),3.32(m,4H),1.82(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.1,157.2,150.9,149.3,148.1,147.4,146.7,134.5,133.0,128.7,124.7,116.6,115.2,72.4,69.5,59.4,58.1,57.3,50.4,41.7,28.7.
其质谱为:MS(EI,m/z):497(M++H).
实施例157
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-三氟甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(4-三氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.24(s,1H),9.84(s,1H),8.65(s,1H),8.10(m,1H),7.32(d,J=4.8Hz,2H),7.19(m,1H),6.67(d,J=4.8Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.56(m,4H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.2,151.3,147.9,147.1,146.4,141.5,134.5,133.4,126.4,125.3,124.7,124.1,116.7,58.4,57.3,48.9,41.2.
其质谱为:MS(EI,m/z):477(M++H).
实施例158
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-三氟甲基苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(4-三氟苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.84(s,1H),8.65(s,1H),8.12(m,1H),7.34(d,J=4.8Hz,2H),7.19(m,1H),6.67(d,J=4.8Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.33(m,4H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,158.3,151.3,145.3,147.1,146.4,140.5,134.5,133.4,127.4,125.3,124.7,123.1,116.7,58.4,57.3,50.9,41.2,29.5.
其质谱为:MS(EI,m/z):491(M++H).
实施例159
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-(乙基氨甲酰基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(4-(乙基氨甲酰基)苯基-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的制备丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.65(s,1H),8.45(s,1H),8.11(m,1H),7.54(d,J=4.8Hz,2H),7.19(m,1H),6.94(d,J=4.8Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.46(m,4H),3.28(q,J=8.0Hz,2H),1.04(t,J=8.0Hz,3H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ167.5,163.5,158.2,150.3,147.9,147.2,146.1,141.4,134.6,133.5,125.5,124.4,118.7,116.7,58.3,57.1,48.9,41.2,34.9,15.6.
其质谱为:MS(EI,m/z):480(M++H).
实施例160
与实施例153的区别在于:中将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-(乙基氨甲酰基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(4-(乙基氨甲酰基)苯基-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的制备丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.65(s,1H),8.45(s,1H),8.11(m,1H),7.54(d,J=4.8Hz,2H),7.19(m,1H),6.94(d,J=4.8Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.45(m,4H),3.18(q,J=8.0Hz,2H),1.85(m,2H),1.04(t,J=8.0Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.1,163.5,158.2,150.0,147.9,147.2,145.1,141.4,134.6,133.5,125.5,123.4,118.7,116.7,58.3,57.1,50.9,41.2,34.9,28.0,15.6.
其质谱为:MS(EI,m/z):494(M++H).
实施例161
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-(N-(3,5-二甲基-4-((2-吗啉乙基)氨甲酰)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(3,5-二甲基-4-((2-吗啉乙基)氨甲酰)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.85(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.97(s,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.56(m,6H),2.46(m,12H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.4,163.5,157.2,150.9,148.4,147.7,147.2,146.6,137.5,134.5,133.4,127.6,124.7,113.7,66.9,58.4,57.3,55.6,54.7,48.9,41.2,37.2,18.9.
其质谱为:MS(EI,m/z):593(M++H).
实施例162
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-(N-(3,5-二甲基-4-((2-吗啉乙基)氨甲酰)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N-(3,5-二甲基-4-((2-吗啉乙基)氨甲酰)苯基)-N’-羟基甲咪)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.77(s,1H),8.83(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.97(s,2H),6.08(s,2H),5.20(s,2H),4.45(s,2H),3.56(m,6H),3.36(m,4H),2.46(m,12H),1.86(m,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ167.4,163.5,157.2,150.9,148.4,147.7,147.2,146.6,137.5,134.5,133.4,127.6,124.7,113.7,66.9,58.4,57.3,55.4,54.3,50.7,41.9,37.2,28.9,18.9.
其质谱为:MS(EI,m/z):607(M++H).
实施例163
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-(3-(二乙基氨基)丙酰氨基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(3-(二乙基氨基)丙酰氨基)苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.84(s,1H),9.89(s,1H),9.80(s,1H),8.65(s,1H),8.11(m,1H),7.34(d,J=4.4Hz,2H),7.19(m,1H),6.77(d,J=4.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.76(t,J=8.4Hz,2H),3.55(m,4H),3.06(q,J=8.8Hz,4H),2.55(t,J=8.4Hz,2H),1.16(t,J=8.8Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ173.4,163.5,157.2,150.9,148.4,147.2,146.6,135.5,134.5,133.4,128.6,124.7,122.6,116.7,58.4,57.3,56.6,49.7,48.9,41.2,33.2,13.9.
其质谱为:MS(EI,m/z):551(M++H).
实施例164
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-(3-(二乙基氨基)丙酰氨基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(3-(二乙基氨基)丙酰氨基)苯基)-N’-羟基甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.89(s,1H),9.40(s,1H),8.65(s,1H),8.11(m,1H),7.34(d,J=4.4Hz,2H),7.19(m,1H),6.77(d,J=4.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.76(t,J=8.4Hz,2H),3.35(m,4H),3.06(q,J=8.8Hz,4H),2.55(t,J=8.4Hz,2H),1.88(m,2H),1.16(t,J=8.8Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ173.4,163.5,157.2,150.9,148.4,147.2,146.6,135.5,134.5,133.4,128.6,124.7,122.6,116.7,58.4,57.3,56.6,51.2,49.7,41.2,33.2,13.3.
其质谱为:MS(EI,m/z):565(M++H).
实施例165
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-丙酰氨基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-丙酰氨基苯基)甲咪基-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),10.20(s,1H),9.87(s,1H),8.65(s,1H),8.11(m,1H),7.35(d,J=6.4Hz,2H),7.19(m,1H),6.75(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.56(m,4H),2.36(q,J=8.4Hz,2H),1.36(t,J=8.4Hz,3H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ172.4,163.5,157.2,150.9,147.7,147.2,146.6,134.5,133.4,132.6,128.6,124.7,122.5,116.7,58.4,57.3,48.9,41.2,30.2,11.9.
其质谱为:MS(EI,m/z):480(M++H).
实施例166
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-丙酰氨基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-丙酰胺基苯基)甲咪基-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.00(s,1H),10.20(s,1H),9.67(s,1H),8.62(s,1H),8.11(m,1H),7.35(d,J=6.4Hz,2H),7.19(m,1H),6.73(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.36(m,4H),2.34(q,J=8.4Hz,2H),186(m,2H),1.16(t,J=8.4Hz,3H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ173.4,162.5,158.2,151.9,147.7,147.2,146.6,134.5,133.4,131.6,128.6,123.7,122.5,115.7,58.4,57.3,50.9,41.2,30.2,28.9,11.9.
其质谱为:MS(EI,m/z):494(M++H).
实施例167
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-吗啉-1-基磺酰基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉-1-基磺酰基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.65(s,1H),8.11(m,1H),7.55(d,J=6.4Hz,2H),7.13(m,1H),6.65(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.36(m,8H),2.96(t,J=8.4Hz,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,150.9,147.7,147.2,146.6,140.5,134.5,133.4,130.6,129.6,124.7,112.5,65.5,58.4,57.3,48.9,47.3,41.2.
其质谱为:MS(EI,m/z):558(M++H).
实施例168
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-吗啉-1-基磺酰基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉氨磺酰基)苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.65(s,1H),8.10(m,1H),7.45(d,J=6.4Hz,2H),7.23(m,1H),6.65(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.66(t,J=8.4Hz,4H)3.36(m,4H),2.96(t,J=8.4Hz,2H),1.84(m,2H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ164.5,157.2,150.3,148.3,147.2,146.2,140.5,134.5,133.4,131.6,129.6,123.7,111.5,65.5,58.4,57.3,50.9,47.3,41.2,28.5.
其质谱为:MS(EI,m/z):572(M++H).
实施例169
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-吗啉-1-基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉-1-基苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.64(s,1H),9.87(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.65(d,J=6.4Hz,2H),6.45(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.76(t,J=8.4Hz,4H),3.45(m,4H),3.16(t,J=8.4Hz,2H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,150.9,147.7,147.2,146.6,139.4,134.5,133.4,128.6,124.7,117.5,113.7,66.5,58.4,57.3,53.3,48.9,41.2.
其质谱为:MS(EI,m/z):494(M++H).
实施例170
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-吗啉-1-基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-吗啉-1-基苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ10.54(s,1H),9.87(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.63(d,J=6.4Hz,2H),6.40(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.76(t,J=8.4Hz,4H),3.35(m,4H),3.16(t,J=8.4Hz,2H),1.88(m,2H)ppm.其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,150.9,147.7,147.2,146.6,139.4,134.5,133.4,128.6,124.7,117.5,113.7,66.5,58.4,57.3,53.3,50.9,41.2,28.4.
其质谱为:MS(EI,m/z):508(M++H).
实施例171
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨乙基)氨基)-N-(4-异丙基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-异丙基苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)乙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.04(s,1H),9.87(s,1H),8.65(s,1H),8.11(m,1H),7.19(m,1H),6.95(d,J=6.4Hz,2H),6.75(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.45(s,2H),3.50(m,4H),2.88(m,1H),1.30(d,J=8.4Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.5,157.2,150.9,147.9,147.2,146.6,138.4,134.9,133.9,133.2,126.6,124.7,116.7,58.4,57.3,48.9,41.2,33.2,23.9.
其质谱为:MS(EI,m/z):451(M++H).
实施例172
与实施例153的区别在于:将(Z)-4-((2-氨乙基)氨基)-N-(4-溴-3-氟苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪(II-1)替换为(Z)-4-((2-氨丙基)氨基)-N-(4-吗啉-1-基)苯基)-N’-羟基-1,2,5-噁二唑-3-甲咪,制得的(Z)-N-(2-((4-(N’-羟基-N-(4-异丙基苯基)甲咪基)-1,2,5-噁二唑-3-基)氨基)丙基)-1,3-二氢-2H-吡咯[3,4-c]吡啶-2-丙烯酰胺的结构式如下:
其核磁共振氢谱为:1H NMR(400MHz,DMSO):δ11.14(s,1H),9.87(s,1H),8.65(s,1H),8.21(m,1H),7.13(m,1H),6.92(d,J=6.4Hz,2H),6.65(d,J=6.4Hz,2H),6.04(s,2H),5.20(s,2H),4.55(s,2H),3.35(m,4H),2.88(m,1H),1.82(m,2H),1.20(d,J=8.4Hz,6H)ppm.
其碳谱为:13C NMR(125MHz,DMSO):δ163.2,156.2,151.9,147.6,147.0,145.6,138.4,134.9,133.9,133.2,126.6,124.7,116.7,58.4,57.3,50.2,41.5,33.5,28.4,23.1.
其质谱为:MS(EI,m/z):465(M++H).
对比试验
体外酶抑制活性的测定
IDO1酶活性的测定方法
首先在微孔板孔内加入15μl磷酸氢钠的缓冲液(PH:7-8),加入5μl含有适量IDO-1酶的反应缓冲液和本发明制备的杂环脲类化合物,混匀,室温反应3小时后,用PE公司的Envision MultilabelReader多功能酶标仪进行检测320nm波长光吸收值,根据吸收比值计算杂环脲类化合物对酶反应的抑制率,用GraphPad软件进行分析计算出杂环脲类化合物的IC50值。
NAMPT酶活性的测试方法
(1)配制缓冲液1,包括:10X NAMPT缓冲液10μL,10X Nicotinamide 10μL,10XPRPP 10μL,10X ATP10μL,NMNAT1酶2μL,加重水48μL使体积达到90μL。
(2)配制缓冲液2,包括:50X WST-1 2μL,50X ADH 2μL,50X Diaphorase 2μL,10XEtOH 10μL,加重水4μL使体积达到20μL。
(3)在微孔板中每孔加入90μL缓冲液1,接着加入2μL 50X的化合物,空白对照组加入2μL DMSO,阳性药对照组加入2μL FK866(1mM)。每孔加入2μL recombinant NAMPT起始酶反应,充分混匀后在30℃孵育60min。反应完成后加入20μL的缓冲液2显色,动态检测反应5-35min的450nm处吸收值。
各个呋咱类化合物的IDO1和NAMPT酶抑制活性测定结果如表1所示。
A:IC50<1nM;B:IC50=100nM-1μM;C:IC50>1μM
从表1中结果可以看出:本发明所制备的呋咱类化合物与阳性对照(INCB24360)相比,具有显著的抑制所列IDO1酶的活性;同时与阳性对照(FK866)相比,具有显著的NAMPT酶抑制活性。
以上对本发明实施例所提供的杂环脲类化合物及其药用组合物和应用,进行了详细介绍,本文中应用了具体个例对本发明的原理及实施方式进行了阐述,以上实施例的说明只是用于帮助理解本发明的方法及其核心思想;同时,对于本领域的一般技术人员,依据本发明的思想,在具体实施方式及应用范围上均会有改变之处,综上所述,本说明书内容不应理解为对本发明的限制。